var title_f34_47_35568="Lung abscess with empyema CT";
var content_f34_47_35568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lung abscess in the right lower lobe with cavitation and narrow neck fistula leading to an empyema in the adjacent pleural space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35568=[""].join("\n");
var outline_f34_47_35568=null;
var title_f34_47_35569="Position of L paratracheal node";
var content_f34_47_35569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Position of the left paratracheal lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kavuru, MS, Mehta, AC. Applied anatomy of the airways. In: Wang, KP, Mehta, AC (Eds), Flexible Bronchoscopy, Blackwell Science Inc, Cambridge, MA 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35569=[""].join("\n");
var outline_f34_47_35569=null;
var title_f34_47_35570="Alveolar hemorrhage CT";
var content_f34_47_35570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonresolving pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT of a patient with acute myelogenous leukemia, severe thrombocytopenia, and the clinical picture of a nonresolving pneumonia. The diagnosis of diffuse alveolar hemorrhage was made at bronchoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan Fein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35570=[""].join("\n");
var outline_f34_47_35570=null;
var title_f34_47_35571="Healing of fractures of olecranon and radial head";
var content_f34_47_35571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Healing of fractures of olecranon and radial head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A and B) Post-reduction radiographs show full reduction of the radial neck and 2 to 3 millimeters of separation of the proximal ulna.",
"    <br>",
"     (C) Healing 3 weeks after reduction.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Paula Schweich, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35571=[""].join("\n");
var outline_f34_47_35571=null;
var title_f34_47_35572="Complications of chronic pancreatitis";
var content_f34_47_35572=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of chronic pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35572/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35572/contributors\">",
"     Steven D Freedman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35572/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35572/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35572/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35572/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/47/35572/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis is an inflammatory condition that results in permanent structural changes in the pancreas, which can lead to impairment of exocrine and endocrine function. The clinical manifestations of this disorder include chronic abdominal pain and pancreatic exocrine and endocrine dysfunction. There may also be an association with pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, chronic pancreatitis can be associated with a variety of complications. The most common are pseudocyst formation and mechanical obstruction of the duodenum and common bile duct; less frequent complications include pancreatic ascites or pleural effusion, splenic vein thrombosis with portal hypertension, and pseudoaneurysm formation, particularly of the splenic artery.",
"   </p>",
"   <p>",
"    These complications of chronic pancreatitis and their management will be reviewed here. Other aspects of the treatment of chronic pancreatitis (principally pain and pancreatic insufficiency) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PSEUDOCYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudocysts develop in approximately 10 percent of patients with chronic pancreatitis. They develop as a result of ductal disruptions rather than from peripancreatic fluid accumulations that lead to pseudocyst formation in the setting of acute pancreatitis. Pseudocysts may be single or multiple, small or large, and can be located either within or outside of the pancreas. Most pseudocysts communicate with the pancreatic ductal system and contain high concentrations of digestive enzymes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The walls of pseudocysts are formed by adjacent structures such as the stomach, transverse mesocolon, gastrocolic omentum, and pancreas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80720 \" href=\"mobipreview.htm?24/33/25108\">",
"     image 1",
"    </a>",
"    ). The lining of pancreatic pseudocysts consists of fibrous and granulation tissue; the lack of an epithelial lining distinguishes pseudocysts from true cystic lesions of the pancreas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most pseudocysts are asymptomatic. They can, however, produce a wide range of clinical problems depending upon the location and extent of the fluid collection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expansion of the pseudocyst can produce abdominal pain, duodenal or biliary obstruction, vascular occlusion, or fistula formation into adjacent viscera, the pleural space, or pericardium.",
"     </li>",
"     <li>",
"      Spontaneous infection with abscess formation.",
"     </li>",
"     <li>",
"      Digestion of an adjacent vessel can result in a pseudoaneurysm, which can produce a sudden expansion of the cyst or gastrointestinal bleeding due to bleeding into the pancreatic duct (hemosuccus pancreaticus).",
"     </li>",
"     <li>",
"      Pancreatic ascites and pleural effusion can result from disruption of the pancreatic duct, leading to fistula formation to the abdomen or chest, or rupture of a pseudocyst with tracking of pancreatic juice into the peritoneal cavity or pleural space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of a pancreatic pseudocyst is usually made by ultrasound or computed tomography (CT) scan. The differential diagnosis includes a variety of other pancreatic cystic neoplasms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for drainage of pseudocysts have evolved. It used to be thought that drainage was indicated if they become greater than 6 cm in diameter or persisted for more than six weeks. However, that approach was challenged by studies which found that pseudocysts can be safely followed up to one year and up to 12 cm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35572/abstract/1\">",
"     1",
"    </a>",
"    ]. Indications for drainage include rapid enlargement, compression of surrounding structures, pain, or signs of infection. Endoscopically derived pancreatograms may be helpful prior to drainage to rule out a stricture of the pancreatic duct which can lead to persistent drainage from the pseudocyst. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BILE DUCT OR DUODENAL OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic obstruction of the bile duct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodenum develops in 5 to 10 percent of patients with chronic pancreatitis. Postprandial pain and early satiety are characteristic of duodenal obstruction, while pain and abnormal liver function tests (including hyperbilirubinemia) are suggestive of a bile duct stricture. These complications are most commonly seen in patients with dilated pancreatic ducts; they are due to either inflammation and fibrosis in the head of the pancreas or to a pseudocyst.",
"   </p>",
"   <p>",
"    Endoscopic retrograde cholangiopancreatography (ERCP) is typically used to make the diagnosis of bile duct obstruction, although magnetic resonance cholangiopancreatography (MRCP) is similar in quality to endoscopically derived cholangiograms, and may ultimately replace diagnostic ERCP (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80729 \" href=\"mobipreview.htm?20/28/20943\">",
"     image 2",
"    </a>",
"    ). Duodenal obstruction can be diagnosed by upper gastrointestinal series, upper endoscopy, or computed tomography (CT) scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage should be performed if a pseudocyst is obstructing the duct. Otherwise, a gastrojejunostomy or choledochoenterostomy is typically performed. Endoscopic stenting may be an option for benign bile duct strictures, but frequently requires several stent changes. The importance of decompression is underscored by the observation that it can reverse secondary biliary fibrosis associated with bile duct obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35572/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17928?source=see_link\">",
"     \"Diagnosis and management of pseudocysts of the pancreas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10168?source=see_link\">",
"     \"Extracorporeal shock wave lithotripsy for pancreatic stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PANCREATIC ASCITES AND PLEURAL EFFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic ascites and pleural effusion may develop following disruption of the pancreatic duct, leading to fistula formation in the abdomen or chest, or rupture of a pseudocyst with tracking of pancreatic juice into the peritoneal cavity or pleural space. Analysis of fluid obtained at paracentesis or thoracentesis is diagnostic; the amylase concentration in the fluid is very high, typically &gt;1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35572/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/168?source=see_link\">",
"     \"Chylous, bloody, and pancreatic ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperative therapies of pancreatic ascites and pleural effusion include repeated aspiration, diuretics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (a long-acting somatostatin analogue), or parenteral nutrition to decrease pancreatic secretion. However, the long-term success of these approaches is uncertain since many patients appear ultimately to require more definitive interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35572/abstract/4\">",
"     4",
"    </a>",
"    ]. If ductal disruption is present, endoscopically-placed stents are effective in the short-term. In one study, for example, resolution of the disrupted pancreatic duct occurred in 16 of 18 patients who had stents placed, and 12 of 14 fluid collections were resolved in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35572/abstract/5\">",
"     5",
"    </a>",
"    ]. At a median follow-up of 16 months, seven patients ultimately required surgery for ongoing pancreatic pain or residual or recurrent fluid collection.",
"   </p>",
"   <p>",
"    Long-term results depend upon the underlying etiology. However, many patients undergo surgery with anastomosis of a Roux-en-Y loop of jejunum to the pancreatic duct or to a leaking pseudocyst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SPLENIC VEIN THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The splenic vein courses along the posterior surface of the pancreas where it can be affected by inflammation leading to thrombosis. Affected patients can develop gastric varices as a result of associated portal hypertension. Splenectomy is usually curative for patients who develop bleeding from gastric varices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PSEUDOANEURYSMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoaneurysm formation is a rare complication of chronic pancreatitis. Affected vessels are in close proximity to the pancreas, including the splenic, hepatic, gastroduodenal, and pancreaticoduodenal arteries. Computed tomography (CT) scan (with and without contrast) or MRI may detect the pseudoaneurysm, which appears as a cystic structure in the pancreas. Doppler ultrasound can show blood flow within the pseudoaneurysm.",
"   </p>",
"   <p>",
"    Mesenteric angiography permits confirmation of the diagnosis, and also provides a means of therapy since embolization of the pseudoaneurysm can be accomplished during the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35572/abstract/6\">",
"     6",
"    </a>",
"    ]. Surgery for bleeding pseudoaneurysms is difficult and associated with a high morbidity and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/26/42401?source=see_link\">",
"       \"Patient information: Pancreatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/45/26322?source=see_link\">",
"       \"Patient information: Chronic pancreatitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pancreatitis is an inflammatory condition that results in permanent structural changes in the pancreas, which can lead to impairment of exocrine and endocrine function. The clinical manifestations of this disorder include chronic abdominal pain and pancreatic exocrine and endocrine dysfunction. Common complications of chronic pancreatitis are pseudocyst formation and mechanical obstruction of the duodenum and common bile duct; less frequent complications include pancreatic ascites or pleural effusion, splenic vein thrombosis with portal hypertension, and pseudoaneurysm formation, particularly of the splenic artery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudocysts develop in approximately 10 percent of patients with chronic pancreatitis. Most pseudocysts are asymptomatic. They can, however, produce a wide range of clinical problems depending upon the location and extent of the fluid collection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pseudocysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic obstruction of the bile duct",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      duodenum develops in 5 to 10 percent of patients with chronic pancreatitis. Postprandial pain and early satiety are characteristic of duodenal obstruction, while pain and abnormal liver function tests (including hyperbilirubinemia) are suggestive of a bile duct stricture. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Bile duct or duodenal obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pancreatic ascites and pleural effusion may develop following disruption of the pancreatic duct, leading to fistula formation in the abdomen or chest, or rupture of a pseudocyst with tracking of pancreatic juice into the peritoneal cavity or pleural space. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pancreatic ascites and pleural effusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The splenic vein courses along the posterior surface of the pancreas where it can be affected by inflammation leading to thrombosis. Affected patients can develop gastric varices as a result of associated portal hypertension. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Splenic vein thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudoaneurysm formation is a rare complication of chronic pancreatitis. Affected vessels are in close proximity to the pancreas, including the splenic, hepatic, gastroduodenal, and pancreaticoduodenal arteries. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pseudoaneurysms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35572/abstract/1\">",
"      Yeo CJ, Bastidas JA, Lynch-Nyhan A, et al. The natural history of pancreatic pseudocysts documented by computed tomography. Surg Gynecol Obstet 1990; 170:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35572/abstract/2\">",
"      Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35572/abstract/3\">",
"      Runyon BA. Amylase levels in ascitic fluid. J Clin Gastroenterol 1987; 9:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35572/abstract/4\">",
"      G&oacute;mez-Cerezo J, Barbado Cano A, Su&aacute;rez I, et al. Pancreatic ascites: study of therapeutic options by analysis of case reports and case series between the years 1975 and 2000. Am J Gastroenterol 2003; 98:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35572/abstract/5\">",
"      Kozarek RA, Ball TJ, Patterson DJ, et al. Endoscopic transpapillary therapy for disrupted pancreatic duct and peripancreatic fluid collections. Gastroenterology 1991; 100:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35572/abstract/6\">",
"      Beattie GC, Hardman JG, Redhead D, Siriwardena AK. Evidence for a central role for selective mesenteric angiography in the management of the major vascular complications of pancreatitis. Am J Surg 2003; 185:96.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5648 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35572=[""].join("\n");
var outline_f34_47_35572=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PSEUDOCYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BILE DUCT OR DUODENAL OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PANCREATIC ASCITES AND PLEURAL EFFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SPLENIC VEIN THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PSEUDOANEURYSMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5648\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5648|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/33/25108\" title=\"diagnostic image 1\">",
"      Pseudocyst of pancreas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/28/20943\" title=\"diagnostic image 2\">",
"      CBD stones MRCP II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/168?source=related_link\">",
"      Chylous, bloody, and pancreatic ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/32/17928?source=related_link\">",
"      Diagnosis and management of pseudocysts of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10168?source=related_link\">",
"      Extracorporeal shock wave lithotripsy for pancreatic stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/45/26322?source=related_link\">",
"      Patient information: Chronic pancreatitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/26/42401?source=related_link\">",
"      Patient information: Pancreatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_47_35573="Colesevelam: Pediatric drug information";
var content_f34_47_35573=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Colesevelam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=see_link\">",
"    see \"Colesevelam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/39/23156?source=see_link\">",
"    see \"Colesevelam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Welchol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lodalis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1006974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent, Bile Acid Sequestrant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1007001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=see_link\">",
"      see \"Colesevelam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Children and Adolescents 10-17 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Once-daily dosing: 3.75 g (6 x 625 mg tablets or 1 packet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Twice-daily dosing: 1.875 g (3 x 625 mg tablets)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to large tablet size, oral suspension is recommended in pediatric patients. Do not administer granules in the dry form (to avoid GI distress).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Welchol&reg;: 3.75 g/packet (30s) [contains phenylalanine 48 mg/packet; citrus flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Welchol&reg;: 625 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1007005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granules for oral suspension: Empty granules into glass, add",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     -1 cup (4-8 ounces) of water; mix well. Administer with meals. Do not take in dry form (to avoid GI distress).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Due to tablet size, it is recommended that any patient who has trouble swallowing tablets should use the oral suspension form. Administer with meal(s) and a liquid.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1006992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1006975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of heterozygous familial hypercholesterolemia in children and adolescent patients [FDA approved in ages 10-17 years (girls &ge;1 year postmenarche)] (see Additional Information for recommendations for initiating treatment in children &ge;8 years); management of elevated LDL in primary hypercholesterolemia (Fredrickson type IIa) when used alone or in combination with an HMG-CoA reductase inhibitor (FDA approved in adults); improve glycemic control in type 2 diabetes mellitus (noninsulin dependent, NIDDM) in conjunction with diet, exercise, and insulin or oral antidiabetic agents (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue (pediatric patients), headache (pediatric patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: CPK increased (pediatric patients), hypertriglyceridemia, hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis, pharyngitis, rhinitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal distension, bowel obstruction, diarrhea, dysphagia, esophageal obstruction, fecal impaction, flatulence, hemorrhoid exacerbation, infection, pancreatitis, transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1006979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bile acid sequestering resins or any component; history bowel obstruction; serum triglyceride concentration &gt;500 mg/dL; history of hypertriglyceridemia-induced pancreatitis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10160673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Granules for suspension contain phenylalanine which must be avoided in patients with phenylketonuria. May decrease absorption of many orally administered medications; avoid concomitant administration with other orally administered medications; separate administration of drug with known interaction by &ge;4 hours. Colesevelam should not be used for glycemic control in type I diabetes mellitus or to treat diabetic ketoacidosis. It is also not indicated in type 2 diabetes mellitus as monotherapy or in combination with dipeptidyl peptidase 4 inhibitors or thiazolidinediones. Colesevelam has not been studied in Fredrickson Type I, III, IV, or V dyslipidemias or in children &lt;10 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1006980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in patients with gastroparesis, other severe GI motility disorders, or a history of major GI tract surgery is not recommended due to constipating effects of colesevelam. Patients with dysphagia or swallowing disorders should use the oral suspension form of colesevelam due to large tablet size and risk for esophageal obstruction. Avoid accidental inhalation or esophageal distress with colesevelam granules; always mix with other fluids prior to ingestion. May increase serum triglyceride concentrations (median increase 5% vs placebo in clinical trials); use caution if serum triglyceride levels are &gt;300 mg/dL; discontinue if triglyceride concentrations exceed 500 mg/dL or hypertriglyceridemia-induced pancreatitis occurs. May interfere with fat-soluble vitamins (A, D, E, K). Chronic use may be associated with bleeding problems due to hypoprothrombinemia from vitamin K deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Bile Acid Sequestrants may decrease the bioavailability of Amiodarone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Bile Acid Sequestrants may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Bile Acid Sequestrants may decrease the serum concentration of Chenodiol.  Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce chenodiol adsorption in the gastrointestinal tract.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens).  Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins).  Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Bile Acid Sequestrants may decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Colesevelam may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Administer cyclosporine at least 4 hours prior to colesevelam.  Monitor for decreased cyclosporine concentrations during concomitant colesevelam therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bile Acid Sequestrants may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethinyl Estradiol: Colesevelam may decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: Bile Acid Sequestrants may decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glimepiride: Colesevelam may decrease the serum concentration of Glimepiride.  Management: Administer glimepiride at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlipiZIDE: Colesevelam may decrease the serum concentration of GlipiZIDE.  Management: Administer glipizide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: Colesevelam may decrease the serum concentration of GlyBURIDE.  Management: Administer glyburide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide.  Management: Unless using this combination to intentionally enhance leflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is not likely to be effective at avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: Bile Acid Sequestrants may decrease the absorption of Lomitapide.  Management: Administer lomitapide at least 4 hours before or after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Bile Acid Sequestrants may decrease the absorption of Loop Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Bile Acid Sequestrants may decrease the absorption of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, bile acid sequestrants may impair the absorption of fat-soluble vitamins.  Management: Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: Bile Acid Sequestrants may decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Bile Acid Sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norethindrone: Colesevelam may decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Olmesartan: Colesevelam may decrease the serum concentration of Olmesartan.  Management: Administer olmesartan at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Colesevelam may decrease the serum concentration of Phenytoin.  Management: Administer phenytoin at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Bile Acid Sequestrants may decrease the serum concentration of Pravastatin.  Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Bile Acid Sequestrants may decrease the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raloxifene: Bile Acid Sequestrants may decrease the absorption of Raloxifene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: Bile Acid Sequestrants may decrease the serum concentration of Teriflunomide.  Management: Unless using this combination to intentionally enhance teriflunomide elimination, consider an alternative to the bile acid sequestrants when possible.  Separating drug administration is unlikely to be effective at avoiding the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Bile Acid Sequestrants may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Bile Acid Sequestrants may decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Bile Acid Sequestrants may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Bile Acid Sequestrants may decrease the serum concentration of Ursodiol.  Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Bile Acid Sequestrants may diminish the therapeutic effect of Vancomycin.  Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Bile Acid Sequestrants may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs.  Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcipotriene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bile Acid Sequestrants may decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F154415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have not been observed in animal reproduction studies. Colesevelam is not absorbed systemically, but may interfere with vitamin absorption; therefore, regular supplementation may not be adequate.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1007007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum cholesterol, LDL, and triglyceride levels should be obtained before initiating treatment and periodically thereafter (in accordance with NCEP guidelines)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1006994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol is the major precursor of bile acid. Colesevelam binds with bile acids in the intestine to form an insoluble complex that is eliminated in feces. This increased excretion of bile acids results in an increased oxidation of cholesterol to bile acid and a lowering of the serum cholesterol. Serum triglyceride levels may increase or remain unchanged with colesevelam treatment. Colesevelam is an exchange resin and may have a higher affinity for anions other than bile acids.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10160801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipid-lowering: Within 2 weeks (maximum effect)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reduction HgA1C (Type II diabetes): 4-6 weeks initial onset, 12-18 weeks maximal effect",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1006996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Insignificant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (0.05%) after 1 month of chronic dosing",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1007011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/39/23156?source=see_link\">",
"      see \"Colesevelam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take medication exactly as directed; do not alter dosage without consulting prescriber. Other medications should be taken 1 hour before or 4 hours after colesevelam. You may experience constipation (increased exercise, fluids, fruit, fiber, or stool softener may help). Report persistent GI upset, severe abdominal pain, skeletal or muscle pain or weakness, or respiratory difficulties.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/47/35573/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/47/35573/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein EA, Marais AD, Szamosi T, et al, \"Colesevelam Hydrochloride: Efficacy and Safety in Pediatric Subjects With Heterozygous Familial Hypercholesterolemia,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2010, 156(2):231-6.e1-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/47/35573/abstract-text/19879596/pubmed\" id=\"19879596\" target=\"_blank\">",
"        19879596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15550 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35573=[""].join("\n");
var outline_f34_47_35573=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154425\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154426\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006974\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007001\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154406\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154391\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007005\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006992\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006975\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154448\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006979\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10160673\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006980\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299081\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154400\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154402\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154415\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007007\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006994\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10160801\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1006996\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007011\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35734?source=related_link\">",
"      Colesevelam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/39/23156?source=related_link\">",
"      Colesevelam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_47_35574="Oxybutynin: Patient drug information";
var content_f34_47_35574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxybutynin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     see \"Oxybutynin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/11/40117?source=see_link\">",
"     see \"Oxybutynin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ditropan XL&reg;;",
"     </li>",
"     <li>",
"      Gelnique 3%&trade;;",
"     </li>",
"     <li>",
"      Gelnique&reg;;",
"     </li>",
"     <li>",
"      Oxytrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxybutynin&reg;;",
"     </li>",
"     <li>",
"      Ditropan XL&reg;;",
"     </li>",
"     <li>",
"      Dom-Oxybutynin;",
"     </li>",
"     <li>",
"      Gelnique&reg;;",
"     </li>",
"     <li>",
"      Mylan-Oxybutynin;",
"     </li>",
"     <li>",
"      Novo-Oxybutynin;",
"     </li>",
"     <li>",
"      Nu-Oxybutyn;",
"     </li>",
"     <li>",
"      Oxybutyn;",
"     </li>",
"     <li>",
"      Oxybutynine;",
"     </li>",
"     <li>",
"      Oxytrol&reg;;",
"     </li>",
"     <li>",
"      PHL-Oxybutynin;",
"     </li>",
"     <li>",
"      PMS-Oxybutynin;",
"     </li>",
"     <li>",
"      Riva-Oxybutynin;",
"     </li>",
"     <li>",
"      Uromax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxybutynin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bowel block, poorly controlled glaucoma, or you are not able to pass urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698205",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may see the tablet shell in your stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash and dry the part of the skin that the gel will be used on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on clean, dry, healthy skin on the belly, thigh, shoulder, or upper arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3760842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you put the gel each day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Let gel dry before covering with clothing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not bathe, shower, or swim for 1 hour after putting on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid fire, flames, or smoking until the gel has dried.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3760843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not let your skin where the gel was used touch anyone else's skin while wearing the gel. Cover the treated skin with clothes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off old patch first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the buttock, belly, or hip. Move the site with each new patch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch loosens, put tape over it to hold it in place.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696442",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed patch as soon as you think about it after taking off the old one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next patch, place the new patch on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Start a new timetable after the patch is put back on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect gel from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10938 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35574=[""].join("\n");
var outline_f34_47_35574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204694\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204695\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024185\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024184\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024189\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024190\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024192\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024187\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024188\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024193\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024194\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=related_link\">",
"      Oxybutynin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/11/40117?source=related_link\">",
"      Oxybutynin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_47_35575="Congenital anomalies of the nose";
var content_f34_47_35575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital anomalies of the nose",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35575/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35575/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35575/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35575/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35575/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35575/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/47/35575/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies are the product of errors in embryogenesis (malformations) or the result of intrauterine events that affect embryonic and fetal growth (deformations and disruptions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/1\">",
"     1",
"    </a>",
"    ]. The more complex the formation of a structure, the more opportunities for malformation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Defects in the formation and growth of the mid-face lead to a variety of malformations. The embryology, clinical features, and management of congenital anomalies of the nose are reviewed here. Congenital anomalies of the ear, upper respiratory, and gastrointestinal tracts are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nose arises from the nasal placodes during the third and fourth weeks of intrauterine life. Each nasal placode is a local thickening of the surface ectoderm on the lateral surface of the head of the embryo, just above the oral stoma. The nasal placodes sink into the mesenchyme to form the depressions that will become the nostrils. Hypertrophy of the tissue surrounding the nasal placodes creates the medial and lateral nasal prominences (",
"    <a class=\"graphic graphic_picture graphicRef71167 \" href=\"mobipreview.htm?16/41/17041\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The nostrils migrate medially, and their soft tissues fuse as the orbits begin their medial migration. The medial nasal processes form the anterior nasal septum, mid-upper lip, and a portion of the anterior hard palate. The nasofrontal process originates from the floor of the anterior cranial fossa as a division of the prosencephalon. The nasofrontal process forms the posterior nasal septum and the ethmoid, nasal, and premaxillary bones. The posterior nasal and oral cavities are separated by the oronasal membrane until the sixth or seventh week of intrauterine life, when the oronasal membrane is resorbed to form the primitive choanae.",
"   </p>",
"   <p>",
"    The prenasal space is located between the nasal and frontal bones during embryogenesis. It extends from the nasal skin to the foramen cecum, an area of the anterior cranial fossa where some prolapse of the dura may occur. The foramen cecum fuses with the fonticulus frontalis to form the cribriform plate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HOLOPROSENCEPHALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improper segmentation and growth of the prosencephalon affects the brain and the face; the series of mid-face and central nervous system (CNS) malformations that result are collectively known as the holoprosencephalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/3\">",
"     3",
"    </a>",
"    ]. The etiology of holoprosencephaly is heterogeneous with both genetic and environmental causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44581?source=see_link&amp;anchor=H14#H14\">",
"     \"Facial clefts and holoprosencephaly\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Holoprosencephalies are characterized by varying degrees of hypotelorism, facial clefts, nasal malformations, and incomplete separation of the two halves of the brain (",
"    <a class=\"graphic graphic_figure graphicRef70880 \" href=\"mobipreview.htm?41/21/42322\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/4\">",
"     4",
"    </a>",
"    ]. These abnormalities may be detected prenatally through ultrasound examination (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64200 \" href=\"mobipreview.htm?22/11/22704\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2762?source=see_link&amp;anchor=H3#H3\">",
"     \"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly\", section on 'Holoprosencephaly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of holoprosencephaly range from an isolated single maxillary incisor to cebocephaly (eg, small mouth, single nostril, and close-set eyes) or cyclopia (",
"    <a class=\"graphic graphic_picture graphicRef60138 \" href=\"mobipreview.htm?39/26/40366\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59143 \" href=\"mobipreview.htm?8/30/8687\">",
"     image 2",
"    </a>",
"    ). The brain may be normal, but incomplete separation of the hemispheres (semilobar holoprosencephaly), single common ventricle (",
"    <a class=\"graphic graphic_picture graphicRef60701 \" href=\"mobipreview.htm?21/16/21775\">",
"     picture 3",
"    </a>",
"    ), and absence of the corpus callosum (alobar holoprosencephaly) are frequent occurrences. As a general rule, the more severe the facial malformations, the worse the abnormalities of the CNS. The more severe forms of holoprosencephaly often are lethal. Intellectual disability (mental retardation) and seizures are common occurrences in survivors. Children with semilobar holoprosencephaly may be asymptomatic and have normal mentation.",
"   </p>",
"   <p>",
"    Holoprosencephaly is associated with pituitary hormone deficiencies including antidiuretic hormone, growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, luteinizing hormone, and follicle stimulating hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/5\">",
"     5",
"    </a>",
"    ]. The hormonal status of children with holoprosencephaly should be evaluated and followed from early childhood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FRONTONASAL DYSPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to holoprosencephaly, frontonasal dysplasia (median cleft face syndrome; number 14 cleft) is characterized by hypertelorism, widow's peak (ie, V-shaped frontal hairline), cranium bifidum occultum (\"cleft skull\"), and a median cleft of the upper lip and palate (",
"    <a class=\"graphic graphic_figure graphicRef66342 \" href=\"mobipreview.htm?20/37/21078\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/6\">",
"     6",
"    </a>",
"    ]. The frontonasal dysplasia sequence is thought to be caused by a primary defect in the nasofrontal process that prevents appropriate migration to the midline. Craniofacial surgery may be required to improve appearance.",
"   </p>",
"   <p>",
"    Most children with frontonasal dysplasia are of normal intelligence. However, many have associated ophthalmologic abnormalities. In one series, 20 of 23 children with frontonasal dysplasia sequence had associated ophthalmologic problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/7\">",
"     7",
"    </a>",
"    ]. Ophthalmologic problems included refractive errors, amblyopia, strabismus, nystagmus, optic nerve hypoplasia, optic nerve coloboma, microphthalmia, cataract, corneal dermoid, and inflammatory retinopathy. Evaluation by an ophthalmologist should be part of the initial management of children with this sequence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6906?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital anomalies and acquired abnormalities of the optic nerve\", section on 'Congenital anomalies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NASAL DERMOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal dermoid sinuses and cysts result from congenital fusion abnormalities at the nasal root. Nasal dermoids are epithelium-lined sinus tracts that extend from the root or tip of the nose through the nasal septum to the anterior cranial fossa.",
"   </p>",
"   <p>",
"    Nasal dermoid sinuses and cysts account for 1 percent of all dermoid cysts and between 3 and 12 percent of dermoids of the head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/8\">",
"     8",
"    </a>",
"    ]. Familial occurrence and autosomal dominant inheritance have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two theories attempt to explain the origin of nasal dermoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cranial origin theory &mdash; Nasal dermoids result from the faulty recession of the dura mater from the prenasal space during normal embryogenesis.",
"     </li>",
"     <li>",
"      The superficial inclusion theory &mdash; Nasal dermoids are formed by the submucosal trapping of ectoderm during the fusion of the lateral nasal processes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nasal dermoids are classically described as noncompressible masses over the nasal dorsum with an associated midline pit or punctum anywhere along the dorsal surface of the nose (",
"    <a class=\"graphic graphic_picture graphicRef79363 \" href=\"mobipreview.htm?39/30/40429\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. The lesions have been variably described as pale, flesh-colored, pearly, or erythematous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. An unusual but important presentation is that of an ill-defined yellowish plaque of the midline nasal dorsum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/19\">",
"     19",
"    </a>",
"    ]. The ability to express sebaceous material or the protrusion of a hair from the pit or punctum suggests the presence of a dermoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ]. The pits may not be noticed unless they have drainage or become infected. They may terminate near the skin surface, but often extend deeply toward the cribriform plate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61438 \" href=\"mobipreview.htm?12/48/13056\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Associated congenital anomalies, such as cleft defects, aural atresia, or hydrocephalus, have been reported in up to 41 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/12\">",
"     12",
"    </a>",
"    ]. The presence of associated anomalies increases the frequency of intracranial extension from 31 to 65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent of the lesion is best determined by a combination of high-resolution axial and coronal computed tomography (CT) and magnetic resonance imaging (MRI) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61438 \" href=\"mobipreview.htm?12/48/13056\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57665 \" href=\"mobipreview.htm?0/50/802\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The use of contrast may differentiate between dermoids, which are avascular, and enhancing lesions, such as hemangiomas or vascular teratomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasal dermoids with intracranial extension should be surgically excised because they increase the risk of CNS infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/23\">",
"     23",
"    </a>",
"    ]. Craniotomy, usually as a staged procedure, is necessary for the excision of nasal dermoids with intracranial extension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/12\">",
"     12",
"    </a>",
"    ]. On the other hand, nasal dermoids that extend to the skull base can be removed through direct incision or the open rhinoplasty approach (ie, degloving the nose from tip to dorsum).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NASAL ENCEPHALOCELES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to nasal dermoids, nasal encephaloceles result from congenital fusion abnormalities at the nasal root. Nasal encephaloceles are herniations of brain, meninges,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebrospinal fluid through a defect in the skull (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82206 \" href=\"mobipreview.htm?23/7/23664\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/22\">",
"     22",
"    </a>",
"    ]. They communicate freely with the subarachnoid space and intracranial ventricular system. They occur in approximately 1 in 4000 live births and are thought to be caused by the defective closure of the anterior neuropore during the fourth week of embryogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nasal encephaloceles may be frontoethmoidal (60 percent), basal (30 percent), or both (10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. Frontoethmoidal cephaloceles usually are evident at birth, presenting as a skin-covered mass at the root of the nose. Lesions that retain a connection with the subarachnoid space enlarge when the infant cries or strains. Basal cephaloceles are not apparent externally; they may cause nasal obstruction or symptoms related to the herniation of basal structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10,24,25\">",
"     10,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical correction of nasal cephaloceles improves appearance and decreases the risk of developing meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/26\">",
"     26",
"    </a>",
"    ]. Cephaloceles typically are treated through a frontal craniotomy. The soft tissue and nose are approached only after dysplastic brain tissue is transected and a watertight closure of the dural defect is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/27\">",
"     27",
"    </a>",
"    ]. Neurologic outcome depends upon the extent of excision that is necessary. Normal mentation is possible after correction of pure meningoceles or small encephaloceles. In contrast, persistent neurologic deficits are common occurrences after excision of large portions of brain parenchyma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NASAL GLIOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal gliomas are benign congenital tumors of ectopic glial tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Their development is thought to be caused by faulty closure of the anterior neuropore. Most of these lesions arise from the lateral nasal wall and cause nasal obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/25\">",
"     25",
"    </a>",
"    ]. They typically appear in proximity to the skull base and must be differentiated from nasal dermoids, polyps, encephaloceles, and hemangiomas by distinctive CT and MRI features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10,30,31\">",
"     10,30,31",
"    </a>",
"    ]. Biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical excision should not be performed until the nature of the lesion is determined by CT and MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ]. Surgical excision is the preferred treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/25\">",
"     25",
"    </a>",
"    ]. Delayed therapy may result in infection or abnormalities of the septum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nasal bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PYRIFORM APERTURE STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pyriform aperture is the anterior bony opening of the nose in the facial skeleton. Congenital stenosis of this opening caused by bony overgrowth causes airway obstruction in newborn infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15,32-34\">",
"     15,32-34",
"    </a>",
"    ]. Infants with congenital pyriform aperture stenosis (CPAS) present with noisy breathing and respiratory distress that worsen with feeding and improve with crying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. CPAS may occur in isolation or in association with other anomalies, including single central maxillary incisor, pituitary abnormalities, craniosynostosis, and holoprosencephaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15,35-39\">",
"     15,35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CT finding of a small nasal opening confirms the diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68161 \" href=\"mobipreview.htm?19/14/19695\">",
"     image 6",
"    </a>",
"    ) and differentiates this malformation from choanal atresia and other causes of anterior nasal obstruction including nasal mucosal edema, nasolacrimal duct cyst, or hypoplasia of the nasal alae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/40\">",
"     40",
"    </a>",
"    ]. Neuroimaging also may detect the presence of associated anomalies requiring intervention (eg, pituitary insufficiency). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Choanal atresia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Nasolacrimal duct cyst'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nasal stenting with paired endotracheal tubes may be sufficient treatment for infants with mild stenosis. However, performing a tracheotomy is necessary to secure the airway in infants with severe stenosis until the child is large enough to tolerate the surgical enlargement of the pyriform aperture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/35\">",
"     35",
"    </a>",
"    ]. Even after surgical repair, the aperture may be relatively small, predisposing the child to developing upper airway obstruction during respiratory infection in the first years of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NASOLACRIMAL DUCT CYST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct cysts (also called dacryocystoceles) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29350?source=see_link&amp;anchor=H6#H6\">",
"     \"Nasolacrimal duct obstruction (dacryostenosis) in children\", section on 'Dacryocystocele'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHOANAL ATRESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choanal atresia is obliteration or blockage of the posterior nasal aperture. Choanal atresia often is associated with bony abnormalities of the pterygoid plates and midfacial growth abnormalities.",
"   </p>",
"   <p>",
"    One etiologic explanation for choanal atresia holds that persistence of the oronasal membrane prevents the joining of the nose and oropharynx. This theory does not account for the associated bony and mid-face abnormalities. An alternate explanation is that alterations in local growth factors result in small or imperforate choanae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/41\">",
"     41",
"    </a>",
"    ]. Most cases involve bony and membranous obstruction to varying degrees (",
"    <a class=\"graphic graphic_picture graphicRef50816 graphicRef79734 \" href=\"mobipreview.htm?42/48/43782\">",
"     picture 5A-B",
"    </a>",
"    ). The separation of choanal atresia into bony or membranous types is artificial.",
"   </p>",
"   <p>",
"    Choanal atresia occurs in approximately one in 7000 live births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ]. It is more common in girls than boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/16\">",
"     16",
"    </a>",
"    ]. Approximately two-thirds of cases are unilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15,42\">",
"     15,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation of choanal atresia varies depending upon whether one or both sides are involved. Individuals with unilateral choanal atresia typically present later in life with unilateral nasal discharge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstruction. Infants with bilateral choanal atresia typically present with upper airway obstruction, noisy breathing, or cyanosis that worsens during feeding and improves when the infant cries.",
"   </p>",
"   <p>",
"    The diagnosis should be suspected if a number 5 or 6 French catheter cannot be passed from the nose to oropharynx a distance of at least 32 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ]. Qualitative measure of nasal airflow, such as the movement of a wisp of cotton under the nostrils or fogging of a mirror adds support to the clinical diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of choanal atresia is confirmed by CT with intranasal contrast that shows narrowing of the posterior nasal cavity at the level of the pterygoid plate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82266 \" href=\"mobipreview.htm?2/30/2543\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Choanal atresia may occur as an isolated anomaly or as part of a multiple congenital anomaly syndrome (eg, Treacher-Collins, CHARGE [coloboma of the iris or choroid, heart defect, atresia of the choanae, retarded growth and development, genitourinary abnormalities, and ear defects with associated deafness], Kallmann, VATER association, Pfeiffer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/43\">",
"     43",
"    </a>",
"    ]. Other congenital anomalies are present in 50 and 60 percent of individuals with unilateral and bilateral choanal atresia, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to a thorough physical examination to detect associated anomalies, cardiology and ophthalmology consultation are warranted for infants with choanal atresia. Associated anomalies include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Facial, nasal, or palatal deformities",
"     </li>",
"     <li>",
"      Polydactylism",
"     </li>",
"     <li>",
"      Congenital heart disease",
"     </li>",
"     <li>",
"      Coloboma of the iris and retina (",
"      <a class=\"graphic graphic_picture graphicRef74086 \" href=\"mobipreview.htm?33/19/34102\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intellectual disability (mental retardation)",
"     </li>",
"     <li>",
"      Malformations of the external ear",
"     </li>",
"     <li>",
"      Esophageal atresia",
"     </li>",
"     <li>",
"      Craniosynostosis",
"     </li>",
"     <li>",
"      Tracheoesophageal fistula",
"     </li>",
"     <li>",
"      Meningocele",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immediate management of infants with choanal atresia includes placement of an oral airway and initiation of gavage feedings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive repair involves transnasal puncture and stenting (",
"    <a class=\"graphic graphic_picture graphicRef66077 \" href=\"mobipreview.htm?9/58/10158\">",
"     picture 7",
"    </a>",
"    ) or endoscopic resection of the posterior nasal septum through a transnasal approach with or without stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The transnasal puncture has fallen out of favor because of an unacceptable rate of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15,42\">",
"     15,42",
"    </a>",
"    ]. Advantages of the transnasal endoscopic approach include clear vision of the operative field and accurate removal of the atretic plate and posterior vomerine bone without damage to surrounding structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15\">",
"     15",
"    </a>",
"    ]. The classic transpalatal approach is reserved for difficult or recurrent cases (",
"    <a class=\"graphic graphic_picture graphicRef51419 \" href=\"mobipreview.htm?13/35/13872\">",
"     picture 8",
"    </a>",
"    ). Recurrent stenosis may occur even after successful surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NASAL SEPTAL DEFORMITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deformities of the nasal septum may be present at birth (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52826 \" href=\"mobipreview.htm?28/22/29038\">",
"     image 8",
"    </a>",
"    ). These may be associated with other congenital mid-face anomalies, particularly cleft lip and palate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/46\">",
"     46",
"    </a>",
"    ], or may appear as isolated deformities. Anterior deviations in an otherwise well-formed nasal septum are thought to arise from intra-uterine pressure effects or intrapartum trauma, which occurs more frequently in normal vaginal deliveries than following cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considerable controversy surrounds the necessity and timing of surgical repair of congenital nasal septal deformities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/48\">",
"     48",
"    </a>",
"    ]. The nasal septum is a major growth center for the mid-face [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/49\">",
"     49",
"    </a>",
"    ]. There is evidence from animal experimentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/50\">",
"     50",
"    </a>",
"    ] and serial clinical observations to suggest that disruption of this growth center may lead to maxillary hypoplasia. Given this information, any corrective surgery should aim for minimal disruption of normal growth centers.",
"   </p>",
"   <p>",
"    Deviations of the nasal tip due to intrapartum pressure effects may resolve spontaneously. More significant nasal septal deformities may cause upper airway obstruction in infants who are obligate nasal breathers. Under such circumstances, surgical correction in the first weeks of life may be necessary. Such surgery may involve intranasal stenting or manipulation of the cartilage of the nasal septum to return it to its normal position on the maxillary crest. Alternatively, conservative septoplasty with resection of fractured or deformed cartilages has been recommended by some authors in severe cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35575/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The holoprosencephalies are a group of mid-face and central nervous system (CNS) malformations that result from improper segmentation and growth of the prosencephalon. The clinical manifestations range from an isolated single maxillary incisor to cebocephaly or cyclopia (",
"      <a class=\"graphic graphic_picture graphicRef60138 \" href=\"mobipreview.htm?39/26/40366\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59143 \" href=\"mobipreview.htm?8/30/8687\">",
"       image 2",
"      </a>",
"      ). Children with holoprosencephaly should be monitored for pituitary hormone deficiencies beginning in early childhood. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Holoprosencephaly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Frontonasal dysplasia (median cleft face syndrome) is characterized by hypertelorism, widow's peak (ie, V-shaped frontal hairline), cleft skull, and a median cleft of the upper lip and palate (",
"      <a class=\"graphic graphic_figure graphicRef66342 \" href=\"mobipreview.htm?20/37/21078\">",
"       figure 2",
"      </a>",
"      ). Associated ophthalmologic abnormalities are common; evaluation by an ophthalmologist should be part of the initial management. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Frontonasal dysplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasal dermoids are epithelium-lined sinus tracts that extend from the root or tip of the nose through the nasal septum to the anterior cranial fossa (",
"      <a class=\"graphic graphic_picture graphicRef79363 \" href=\"mobipreview.htm?39/30/40429\">",
"       picture 4",
"      </a>",
"      ). The extent of the lesion is best determined by a combination of high-resolution axial and coronal computed tomography (CT) and magnetic resonance imaging. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nasal dermoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasal encephaloceles are herniations of brain, meninges,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cerebrospinal fluid through a defect in the skull (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82206 \" href=\"mobipreview.htm?23/7/23664\">",
"       image 5",
"      </a>",
"      ). Those containing brain tissue are termed encephaloceles. They may communicate with the subarachnoid space and, occasionally the ventricular system. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nasal encephaloceles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasal gliomas are benign congenital tumors of ectopic glial tissue. Nasal gliomas must be differentiated radiographically from nasal dermoids, polyps, encephaloceles, and hemangiomas. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nasal gliomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital pyriform aperture stenosis (CPAS) causes airway obstruction in newborn infants. Infants with congenital pyriform aperture stenosis (CPAS) present with noisy breathing and respiratory distress. These symptoms worsen with feeding and improve with crying. The CT finding of a small nasal opening confirms the diagnosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68161 \" href=\"mobipreview.htm?19/14/19695\">",
"       image 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pyriform aperture stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Choanal atresia is obliteration or blockage of the posterior nasal aperture. Infants with bilateral choanal atresia typically present with upper airway obstruction, noisy breathing, or cyanosis that worsens during feeding and improves with crying. Patients with unilateral choanal atresia generally present later in life. The diagnosis is confirmed by CT with intranasal contrast (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82266 \" href=\"mobipreview.htm?2/30/2543\">",
"       image 7",
"      </a>",
"      ). Infants with choanal atresia should be evaluated for associated cardiac and ophthalmologic anomalies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choanal atresia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital nasal septal deformities (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52826 \" href=\"mobipreview.htm?28/22/29038\">",
"       image 8",
"      </a>",
"      ) may cause upper airway obstruction in infants who are obligate nose breathers. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nasal septal deformities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jones KL. Dysmorphology approach and classification. In: Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/2\">",
"      Harley EH. Pediatric congenital nasal masses. Ear Nose Throat J 1991; 70:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/3\">",
"      Cohen MM Jr. Perspectives on holoprosencephaly: Part III. Spectra, distinctions, continuities, and discontinuities. Am J Med Genet 1989; 34:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/4\">",
"      Cohen MM Jr, Jir&aacute;sek JE, Guzman RT, et al. Holoprosencephaly and facial dysmorphia: nosology, etiology and pathogenesis. Birth Defects Orig Artic Ser 1971; 7:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/5\">",
"      Traggiai C, Stanhope R. Endocrinopathies associated with midline cerebral and cranial malformations. J Pediatr 2002; 140:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/6\">",
"      Chervenak FA, Tortora M, Mayden K, et al. Antenatal diagnosis of median cleft face syndrome: sonographic demonstration of cleft lip and hypertelorism. Am J Obstet Gynecol 1984; 149:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/7\">",
"      Roarty JD, Pron GE, Siegel-Bartelt J, et al. Ocular manifestations of frontonasal dysplasia. Plast Reconstr Surg 1994; 93:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/8\">",
"      Bratton C, Suskind DL, Thomas T, Kluka EA. Autosomal dominant familial frontonasal dermoid cysts: a mother and her identical twin daughters. Int J Pediatr Otorhinolaryngol 2001; 57:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/9\">",
"      Plewes JL, Jacobson I. Familial frontonasal dermoid cysts. Report of four cases. J Neurosurg 1971; 34:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/10\">",
"      Myer CM 3rd, Cotton RT. Nasal obstruction in the pediatric patient. Pediatrics 1983; 72:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/11\">",
"      MacGregor FB, Geddes NK. Nasal dermoids: the significance of a midline punctum. Arch Dis Child 1993; 68:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/12\">",
"      Denoyelle F, Ducroz V, Roger G, Garabedian EN. Nasal dermoid sinus cysts in children. Laryngoscope 1997; 107:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/13\">",
"      Cambiaghi S, Micheli S, Talamonti G, Maffeis L. Nasal dermoid sinus cyst. Pediatr Dermatol 2007; 24:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/14\">",
"      Rahbar R, Shah P, Mulliken JB, et al. The presentation and management of nasal dermoid: a 30-year experience. Arch Otolaryngol Head Neck Surg 2003; 129:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/15\">",
"      Szeremeta W, Parikh TD, Widelitz JS. Congenital nasal malformations. Otolaryngol Clin North Am 2007; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/16\">",
"      Lee WT, Koltai PJ. Nasal deformity in neonates and young children. Pediatr Clin North Am 2003; 50:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/17\">",
"      Frodel JL, Larrabee WF, Raisis J. The nasal dermoid. Otolaryngol Head Neck Surg 1989; 101:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/18\">",
"      Bradley PJ, Singh SD. Congenital nasal masses: diagnosis and management. Clin Otolaryngol Allied Sci 1982; 7:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/19\">",
"      Julapalli MR, Cohen BA, Hollier LH, Metry DW. Congenital, ill-defined, yellowish plaque: the nasal dermoid. Pediatr Dermatol 2006; 23:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/20\">",
"      Lindbichler F, Braun H, Raith J, et al. Nasal dermoid cyst with a sinus tract extending to the frontal dura mater: MRI. Neuroradiology 1997; 39:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/21\">",
"      Lowe LH, Booth TN, Joglar JM, Rollins NK. Midface anomalies in children. Radiographics 2000; 20:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/22\">",
"      Saettele M, Alexander A, Markovich B, et al. Congenital midline nasofrontal masses. Pediatr Radiol 2012; 42:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/23\">",
"      Paller AS, Pensler JM, Tomita T. Nasal midline masses in infants and children. Dermoids, encephaloceles, and gliomas. Arch Dermatol 1991; 127:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/24\">",
"      Hoving EW. Nasal encephaloceles. Childs Nerv Syst 2000; 16:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/25\">",
"      Rahbar R, Resto VA, Robson CD, et al. Nasal glioma and encephalocele: diagnosis and management. Laryngoscope 2003; 113:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/26\">",
"      Izquierdo JM, Gil-Carcedo LM. Recurrent meningitis and transethmoidal intranasal meningoencephalocele. Dev Med Child Neurol 1988; 30:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/27\">",
"      Turgut M, Ozcan OE, Benli K, et al. Congenital nasal encephalocele: a review of 35 cases. J Craniomaxillofac Surg 1995; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/28\">",
"      Chang KC, Leu YS. Nasal glioma: a case report. Ear Nose Throat J 2001; 80:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/29\">",
"      Puppala B, Mangurten HH, McFadden J, et al. Nasal glioma. Presenting as neonatal respiratory distress. Definition of the tumor mass by MRI. Clin Pediatr (Phila) 1990; 29:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/30\">",
"      Hoeger PH, Schaefer H, Ussmueller J, Helmke K. Nasal glioma presenting as capillary haemangioma. Eur J Pediatr 2001; 160:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/31\">",
"      Levine MR, Kellis A, Lash R. Nasal glioma masquerading as a capillary hemangioma. Ophthal Plast Reconstr Surg 1993; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/32\">",
"      Brown OE, Myer CM 3rd, Manning SC. Congenital nasal pyriform aperture stenosis. Laryngoscope 1989; 99:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/33\">",
"      Rombaux P, Hamoir M, Francois G, et al. Congenital nasal pyriform aperture stenosis in newborn: report on three cases. Rhinology 2000; 38:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/34\">",
"      Ramadan H, Ortiz O. Congenital nasal pyriform aperture (bony inlet) stenosis. Otolaryngol Head Neck Surg 1995; 113:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/35\">",
"      Van Den Abbeele T, Triglia JM, Fran&ccedil;ois M, Narcy P. Congenital nasal pyriform aperture stenosis: diagnosis and management of 20 cases. Ann Otol Rhinol Laryngol 2001; 110:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/36\">",
"      Godil MA, Galvin-Parton P, Monte D, et al. Congenital nasal pyriform aperture stenosis associated with central diabetes insipidus. J Pediatr 2000; 137:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/37\">",
"      Lo FS, Lee YJ, Lin SP, et al. Solitary maxillary central incisor and congenital nasal pyriform aperture stenosis. Eur J Pediatr 1998; 157:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/38\">",
"      Beregsz&agrave;szi M, L&eacute;ger J, Garel C, et al. Nasal pyriform aperture stenosis and absence of the anterior pituitary gland: report of two cases. J Pediatr 1996; 128:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/39\">",
"      Guilmin-Cr&eacute;pon S, Garel C, Baumann C, et al. High proportion of pituitary abnormalities and other congenital defects in children with congenital nasal pyriform aperture stenosis. Pediatr Res 2006; 60:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/40\">",
"      Murali H, Hurt H. Nasal molding: a cultural practice causing respiratory distress in a term infant. J Pediatr 2004; 144:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/41\">",
"      Keller JL, Kacker A. Choanal atresia, CHARGE association, and congenital nasal stenosis. Otolaryngol Clin North Am 2000; 33:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/42\">",
"      Hengerer AS, Brickman TM, Jeyakumar A. Choanal atresia: embryologic analysis and evolution of treatment, a 30-year experience. Laryngoscope 2008; 118:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/43\">",
"      Burrow TA, Saal HM, de Alarcon A, et al. Characterization of congenital anomalies in individuals with choanal atresia. Arch Otolaryngol Head Neck Surg 2009; 135:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/44\">",
"      Friedman NR, Mitchell RB, Bailey CM, et al. Management and outcome of choanal atresia correction. Int J Pediatr Otorhinolaryngol 2000; 52:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/45\">",
"      Cedin AC, Atallah AN, Andriolo RB, et al. Surgery for congenital choanal atresia. Cochrane Database Syst Rev 2012; :CD008993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/46\">",
"      Yoon YJ, Perkiomaki MR, Tallents RH, et al. Association of nasomaxillary asymmetry in children with unilateral cleft lip and palate and their parents. Cleft Palate Craniofac J 2003; 40:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/47\">",
"      Alpini D, Corti A, Brusa E, Bini A. Septal deviation in newborn infants. Int J Pediatr Otorhinolaryngol 1986; 11:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/48\">",
"      B&eacute;jar I, Farkas LG, Messner AH, Crysdale WS. Nasal growth after external septoplasty in children. Arch Otolaryngol Head Neck Surg 1996; 122:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/49\">",
"      Grymer LF, Bosch C. The nasal septum and the development of the midface. A longitudinal study of a pair of monozygotic twins. Rhinology 1997; 35:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/50\">",
"      Meeuwis J, Verwoerd-Verhoef HL, Verwoerd CD. Normal and abnormal nasal growth after partial submucous resection of the cartilaginous septum. Acta Otolaryngol 1993; 113:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35575/abstract/51\">",
"      Emami AJ, Brodsky L, Pizzuto M. Neonatal septoplasty: case report and review of the literature. Int J Pediatr Otorhinolaryngol 1996; 35:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6301 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35575=[""].join("\n");
var outline_f34_47_35575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HOLOPROSENCEPHALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FRONTONASAL DYSPLASIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NASAL DERMOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NASAL ENCEPHALOCELES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NASAL GLIOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PYRIFORM APERTURE STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NASOLACRIMAL DUCT CYST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHOANAL ATRESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NASAL SEPTAL DEFORMITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6301\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6301|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/11/22704\" title=\"diagnostic image 1\">",
"      Holoprosencephaly sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/30/8687\" title=\"diagnostic image 2\">",
"      Cyclopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/48/13056\" title=\"diagnostic image 3\">",
"      Nasal dermoid radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/50/802\" title=\"diagnostic image 4\">",
"      Nasal dermoid with intracranial extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/7/23664\" title=\"diagnostic image 5\">",
"      Nasal encephalocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/14/19695\" title=\"diagnostic image 6\">",
"      Pyriform aperture stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/30/2543\" title=\"diagnostic image 7\">",
"      CT choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/22/29038\" title=\"diagnostic image 8\">",
"      Nasal septal deformity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6301|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/21/42322\" title=\"figure 1\">",
"      Holoprosencephaly spectrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/37/21078\" title=\"figure 2\">",
"      Types of frontonasal dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6301|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/41/17041\" title=\"picture 1\">",
"      Nasal embryology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/26/40366\" title=\"picture 2\">",
"      Cebocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/16/21775\" title=\"picture 3\">",
"      Holoprosencephaly brain section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/30/40429\" title=\"picture 4\">",
"      Nasal dermoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/32/4611\" title=\"picture 5A\">",
"      Anatomy choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/11/13488\" title=\"picture 5B\">",
"      Endoscopy choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/19/34102\" title=\"picture 6\">",
"      Iris coloboma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/58/10158\" title=\"picture 7\">",
"      Nasal stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/35/13872\" title=\"picture 8\">",
"      Choanal atresia repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/34/44581?source=related_link\">",
"      Facial clefts and holoprosencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29350?source=related_link\">",
"      Nasolacrimal duct obstruction (dacryostenosis) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/44/2762?source=related_link\">",
"      Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_47_35576="Fever in the intensive care unit";
var content_f34_47_35576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fever in the intensive care unit",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35576/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35576/contributors\">",
"     Graeme MacLaren, MBBS, FCICM, FRACP, FCCP, FCCM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35576/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35576/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35576/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35576/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35576/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/47/35576/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common abnormality in the intensive care unit (ICU), which prompts important diagnostic and treatment decisions. The definition, differential diagnosis, diagnostic evaluation, and management of fever in the ICU are reviewed here. The pathophysiology of fever is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8361?source=see_link\">",
"     \"Pathophysiology and treatment of fever in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22450950\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal body temperature is approximately 37.0&ordm;C (98.6&ordm;F), although this varies with the time of day and the method of measurement used. The definition of fever is arbitrary; as the temperature that defines fever is lowered, its sensitivity increases and its specificity decreases. A joint task force from the American College of Critical Care Medicine and the Infectious Diseases Society of America defined fever as a body temperature of 38.3&ordm;C (101&ordm;F) or higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/1\">",
"     1",
"    </a>",
"    ]. We adhere to this definition in this review because it is widely accepted. It is reasonable to use a lower temperature to define fever in immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TEMPERATURE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional means of measuring temperature in the ICU include intravascular, intravesicular (ie, bladder), rectal, and oral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. The gold standard is the thermistor on a pulmonary artery catheter, although these are used infrequently and may give unreliable temperature readings if the catheter is used to rapidly administer volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/1\">",
"     1",
"    </a>",
"    ]. Regardless of which method is chosen, the same method and site of measurement should be used repeatedly to facilitate the trending of serial measurements. Alternative methods, such as axillary, temporal artery, tympanic, and chemical dot monitors, should not be used because they are inaccurate during critical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/1,6-12\">",
"     1,6-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22451247\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever complicates up to 70 percent of all ICU admissions and is often due to an infection or another serious condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one observational study of 24,204 adult ICU admissions, fever &ge;39.5&ordm;C (103&ordm;F) was associated with an increase in mortality (20 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/14\">",
"     14",
"    </a>",
"    ]. Fever has also been associated with an increased length of stay, increased cost of care, and poorer outcomes in patients with traumatic head injury, subarachnoid hemorrhage, or pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/13,15-21\">",
"     13,15-21",
"    </a>",
"    ]. The same associations probably exist with other conditions that have not been studied. Fever may prompt unnecessary investigations and lead to inappropriate antibiotic use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sources of fever in the ICU may be infectious (",
"    <a class=\"graphic graphic_table graphicRef73551 \" href=\"mobipreview.htm?5/51/5948\">",
"     table 1",
"    </a>",
"    ) or noninfectious (",
"    <a class=\"graphic graphic_table graphicRef68779 \" href=\"mobipreview.htm?21/63/22524\">",
"     table 2",
"    </a>",
"    ). The relative frequency of infectious and noninfectious fevers varies according to the population being studied and the definition of infection that is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/13\">",
"     13",
"    </a>",
"    ]. Distinguishing between infectious and noninfectious fevers is challenging, but the magnitude of the fever may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/7,22,23\">",
"     7,22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fevers between 38.3&ordm;C (101&ordm;F) and 38.8&ordm;C (101.8&ordm;F) may be infectious or noninfectious. The differential diagnosis is longest in this range; fortunately, most noninfectious sources of fever can be excluded by a detailed history and physical examination.",
"     </li>",
"     <li>",
"      Fevers between 38.9 (102&ordm;F) and 41&ordm;C (105.8&ordm;F) can be assumed to be infectious.",
"     </li>",
"     <li>",
"      Fevers &ge;41.1&ordm;C (106&ordm;F) are usually noninfectious. Examples include drug fever, transfusion reactions, adrenal insufficiency, thyroid storm, neuroleptic malignant syndrome, heat stroke, and malignant hyperthermia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=see_link\">",
"       \"Severe hyperthermia (heat stroke) in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infectious causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many infectious sources of fever (",
"    <a class=\"graphic graphic_table graphicRef73551 \" href=\"mobipreview.htm?5/51/5948\">",
"     table 1",
"    </a>",
"    ). The most common in the ICU include ventilator-associated pneumonia, intravascular catheter-related infections, surgical site infections, catheter-related urinary tract infections, and bacteremia from these and other sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventilator-associated pneumonia (VAP) &ndash; VAP is usually suspected when a patient who has been receiving mechanical ventilation for more than 48 hours develops a fever that is accompanied by a new or progressive pulmonary infiltrate, leukocytosis, and purulent tracheobronchial secretions. These signs may be accompanied by an increased respiratory rate, increased minute volume, decreased tidal volume, decreased oxygenation, or the need for more ventilatory support or inspired oxygen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link\">",
"       \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravascular catheter-related infection &ndash; Intravascular catheter-related infections commonly present as a fever without localizing symptoms or signs. Alternative presentations include cellulitis at the insertion site, purulent drainage from the insertion site, incidentally detected bacteremia, sepsis (fever, tachycardia, tachypnea, leukocytosis), severe sepsis (sepsis plus organ dysfunction), or septic shock (eg, severe sepsis plus shock). Rarely, a patient may present with suppurative thrombophlebitis, endocarditis, or septic abscesses. Arterial catheters have comparable infection rates to central venous catheters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=see_link&amp;anchor=H14#H14\">",
"       \"Arterial catheterization techniques for invasive monitoring\", section on 'Infection'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=see_link&amp;anchor=H11#H11\">",
"       \"Complications of central venous catheters and their prevention\", section on 'Infection and thrombosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical site infection &ndash; A surgical site infection should be considered in any post-operative patient with a fever. Most surgical site infections occur one to four weeks after surgery, although they may occasionally occur during the first postoperative week or more than a month after surgery. The clinical manifestations and likely pathogen depend upon the surgical site. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19178?source=see_link\">",
"       \"Postoperative fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catheter-related urinary tract infections &ndash; The incidence of catheter-related urinary tract infections has probably been overestimated because many studies did not distinguish asymptomatic bacteriuria from a genuine urinary tract infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/25\">",
"       25",
"      </a>",
"      ]. Catheter-related urinary tract infections may present as a fever without localizing symptoms or signs. They may also present with symptoms and signs of cystitis (fever, suprapubic pain, hematuria, pyuria), pyelonephritis (fever, chills, flank pain, costovertebral angle tenderness, nausea, and vomiting), or urosepsis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=see_link\">",
"       \"Urinary tract infection associated with urethral catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacteremia &ndash; Bacteremia may be secondary to any of the above infections, as well as many others. Fever may be the only sign of bacteremia, although it can rapidly progress to sepsis, severe sepsis, or septic shock. Transfusion-transmitted bacterial infection is a rare, but life-threatening, complication of hospital care that does not always occur during transfusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10471?source=see_link\">",
"       \"Transfusion transmitted bacterial infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sinusitis &ndash; Sinusitis occurs in eight percent of all ICU patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/26\">",
"       26",
"      </a>",
"      ], but is more common among mechanically ventilated patients who have sinus opacification on imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/27\">",
"       27",
"      </a>",
"      ]. It most typically manifests as fever without localizing symptoms and signs, since most patients are mechanically ventilated and unable to communicate the presence of a headache and sinus tenderness. Purulent nasal drainage is occasionally present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link&amp;anchor=H12#H12\">",
"       \"Endotracheal tube management and complications\", section on 'Sinusitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the infections described above have the potential to progress to sepsis, severe sepsis, and septic shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link&amp;anchor=H2#H2\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Noninfectious causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many noninfectious sources of fever in the ICU (",
"    <a class=\"graphic graphic_table graphicRef68779 \" href=\"mobipreview.htm?21/63/22524\">",
"     table 2",
"    </a>",
"    ). In most cases, the fever is not the only sign and, therefore, the cause can usually be identified with a detailed history and physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/7\">",
"     7",
"    </a>",
"    ]. The noninfectious causes of fever may be conceptualized as those that are accompanied by distributive shock and those that are not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link&amp;anchor=H6#H6\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Distributive'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Noninfectious fever without shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious causes of fever that are usually not accompanied by shock include transfusion reactions, drug fever, certain intra-abdominal conditions (eg, acalculous cholecystitis, mesenteric ischemia, pancreatitis), and thromboembolic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-hemolytic transfusion reaction &ndash; Fever is the most common sign of a non-hemolytic transfusion reaction. It generally occurs within one to six hours after the initiation of a transfusion of red blood cells or platelets and may be accompanied by chills and mild dyspnea. Non-hemolytic reactions are benign with no lasting sequelae, but can be uncomfortable. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link&amp;anchor=H3#H3\">",
"       \"Immunologic blood transfusion reactions\", section on 'Febrile nonhemolytic reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug fever &ndash; Drug fever is a diagnostic challenge. It can occur several days after the initiation of the drug, can take several days to subside after cessation of the drug, and can produce high fevers (ie, &gt;38.9&ordm;C [102&ordm;F]) without other signs. The true incidence is unknown. It is essentially a diagnosis of exclusion unless other signs of hypersensitivity (eg, rash) are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2456?source=see_link\">",
"       \"Drug fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acalculous cholecystitis &ndash; Acalculous cholecystitis is associated with a variety of clinical conditions (",
"      <a class=\"graphic graphic_table graphicRef82539 \" href=\"mobipreview.htm?2/14/2284\">",
"       table 3",
"      </a>",
"      ). It generally presents with fever, leukocytosis, and vague abdominal discomfort. A right upper quadrant mass may be palpable. An insidious presentation is associated with gallbladder gangrene and perforation. Acalculous cholecystitis may have a mortality rate as high as 30 to 40 percent, even with treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6742?source=see_link\">",
"       \"Acalculous cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mesenteric ischemia &ndash; Fever is a late sign in both arterial and venous mesenteric ischemia. It usually signifies bowel infarction, by which time other signs have usually developed such as abdominal tenderness, hematochezia, or lactic acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. The abdominal tenderness is typically periumbilical, may be severe and out of proportion to the physical exam findings, and may be accompanied by nausea and vomiting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"       \"Acute mesenteric ischemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute pancreatitis &ndash; Acute pancreatitis is typically accompanied by abdominal pain, tenderness, and distension, as well as nausea and vomiting. Abdominal pain due to pancreatitis is typically improved by leaning forward. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deep vein thrombosis (DVT) &ndash; DVT is common among ICU patients, with an incidence that has been estimated to be 12 to 33 percent depending upon the patient populations studied and type of prophylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. However, DVT is a rare cause of fever. More common manifestations of DVT include asymmetric extremity edema, pain, or erythema. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary embolism (PE) &ndash; The Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) study about PE in hospitalized patients (not necessarily ICU patients) detected fever with the following frequency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/35,36\">",
"       35,36",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link\">",
"       \"Overview of acute pulmonary embolism\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fourteen percent when defined as &gt;37.8&ordm;C (&gt;100&ordm;F)",
"     </li>",
"     <li>",
"      Six percent when defined as &gt;38.3&ordm;C (&gt;101&ordm;F)",
"     </li>",
"     <li>",
"      One and one half percent when defined as &gt;38.9&ordm;C (&gt;102&ordm;F)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Noninfectious fever with shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious causes of fever that are frequently accompanied by shock include adrenal crisis (ie, acute adrenal insufficiency) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], thyroid storm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/39\">",
"     39",
"    </a>",
"    ], and an acute hemolytic transfusion reaction. The fever is often &gt;38.9&ordm;C (&gt;102&ordm;F) and the shock is distributive, which is characterized by hypotension, warm extremities, a hyperdynamic precordium (tachycardia, prominent heart sounds), oliguria, altered mental status, and metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link&amp;anchor=H6#H6\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Distributive'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenal crisis &ndash; An adrenal crisis usually occurs in patients with previously undiagnosed adrenal insufficiency who are subjected to a serious infection or other major stress, patients with known adrenal insufficiency who do not take more glucocorticoid during a serious infection or other major stress, patients with acute bilateral adrenal infarction or hemorrhage, or patients whose chronic glucocorticoid therapy is abruptly withdrawn. Distributive shock is the predominant manifestation of an adrenal crisis, but fever, nausea, vomiting, abdominal pain, weakness, fatigue, lethargy, hypoglycemia, confusion, or coma may also be present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations of adrenal insufficiency in adults\", section on 'Adrenal crisis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid storm &ndash; Thyroid storm refers to severe, life-threatening thyrotoxicosis. It is often precipitated by an acute stressor, such as surgery, infection, trauma, or an acute iodine load. Clinical manifestations may include severe fever (&gt;40&ordm;C [&gt;104&ordm;F]), distributive shock, severe tachycardia (&gt;140",
"      <span class=\"nowrap\">",
"       beat/min),",
"      </span>",
"      congestive heart failure, nausea, vomiting, diarrhea, agitation, delirium, psychosis, stupor, and coma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33655?source=see_link\">",
"       \"Thyroid storm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute hemolytic transfusion reaction &ndash; An acute hemolytic transfusion reaction is a medical emergency that results from the rapid destruction of donor red blood cells by recipient antibodies. It is usually due to ABO incompatibility. Some acquired alloantibodies are occasionally implicated. Common clinical manifestations include fever, chills, distributive shock, disseminated intravascular coagulation, and acute kidney injury. Flank pain, red or brown urine, and bleeding occur less often. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=see_link&amp;anchor=H7#H7\">",
"       \"Immunologic blood transfusion reactions\", section on 'Acute hemolytic reactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough review of the medical history and a full physical examination should be performed whenever a patient develops an unexplained fever in the ICU. Blood cultures are the only mandatory diagnostic tests in patients with a new fever; the rationale is that clinical findings cannot reliably exclude bacteremia and mortality is high without appropriate treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/40\">",
"     40",
"    </a>",
"    ]. Further investigation may be indicated depending upon the clinical assessment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sputum &ndash; Sputum Gram stain and culture are indicated for febrile patients with any of the following findings: new sputum production; a change in the color, amount, or thickness of their sputum; a new or progressive pulmonary infiltrate; an increased respiratory rate; an increased minute volume; a decreased tidal volume; decreased oxygenation; needing more ventilatory support; or requiring more inspired oxygen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link\">",
"       \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"       \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urine &ndash; Urinalysis and urine culture are indicated for febrile patients with a urethral catheter, urinary obstruction, renal calculi, recent genitourinary surgery or trauma, or neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=see_link\">",
"       \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest imaging &ndash; A chest radiograph is easily obtainable in the ICU and worthwhile in many patients with respiratory symptoms or signs. It may detect a new or progressive pulmonary infiltrate, distinguish pneumonia from tracheobronchitis, or identify a respiratory source of fever other than pneumonia or tracheobronchitis that would otherwise be missed because it is not associated with sputum production. However, chest radiographs are less helpful and, therefore, should be used more judiciously in patients with known pleural effusions, acute lung injury, or acute respiratory distress syndrome because such abnormalities may obscure other findings. Computed tomography (CT) should be reserved for the clarification of abnormal chest radiographic findings.",
"     </li>",
"     <li>",
"      Laboratory studies &ndash; Transaminase, bilirubin, alkaline phosphatase, amylase, lipase, and lactate measurements are indicated for patients with abdominal pain or whose abdominal exam cannot be reliably assessed due to sedation or coma. Serum sodium, potassium, glucose, and cortisol levels should be drawn if adrenal insufficiency is possible. Thyroid stimulating hormone (TSH), T3, and T4 levels should be drawn if thyroid storm is possible. And, blood should be drawn for measurement of direct antiglobulin test, plasma free hemoglobin, and haptoglobin, as well as a repeat blood type and cross-match if an acute hemolytic transfusion reaction is suspected.",
"      <br/>",
"      <br/>",
"      Procalcitonin (PCT) and the endotoxin activity assay are adjunctive diagnostic tools for distinguishing fever due to infection from noninfectious fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/1\">",
"       1",
"      </a>",
"      ]. We believe that such assays should be used as a last resort until the benefits of each are clarified, even though several professional organizations have endorsed them as reasonable measures. Currently, the body of evidence for PCT testing is conflicting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/41,42\">",
"       41,42",
"      </a>",
"      ] and the body of evidence for the endotoxin activity assay is scarce [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. C-reactive protein (CRP) has also been studied as a biomarker for identifying infection, but it appears less promising because it lacks specificity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/45,46\">",
"       45,46",
"      </a>",
"      ], rises later than PCT, doesn&rsquo;t correlate as well with severity of disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/47\">",
"       47",
"      </a>",
"      ], and tends to be lower among patients with liver disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/48\">",
"       48",
"      </a>",
"      ]. Both PCT and CRP predict mortality in ICU patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abdominal imaging &ndash; Abdominal imaging is indicated for patients with symptoms or signs of an intraabdominal process, but for whom the laboratory testing has not identified the cause of the symptoms or signs. It is also indicated for patients who have a reason to have an intraabdominal infection (eg, recent abdominal surgery) and no alternative source of the fever has been identified, even if there are no symptoms or signs of an abdominal process. Finally, abdominal imaging may be indicated if laboratory testing suggests a possible intraabdominal process, but the results are insufficient to identify the exact abnormality. As an example, in a patient with fever, transaminitis, and hyperbilirubinemia, a right upper quadrant ultrasound exam may determine whether there is acalculous cholecystitis, choledocholithiasis, or a primary hepatic condition.",
"     </li>",
"     <li>",
"      Sinus evaluation &ndash; Evaluation for sinusitis is appropriate for mechanically ventilated patients who have purulent nasal drainage or whose evaluation has otherwise been completely negative. The evaluation begins with a radiographic evaluation looking for sinus opacification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. CT is the preferred modality, but sinus radiographs and sinus ultrasound are reasonable alternatives. Culture of sinus fluid obtained by endoscopic-guided middle meatal aspiration is indicated for patients with sinus opacification and no other cause for fever. Interpretation of the culture results and the role of empiric therapy are discussed separately. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link&amp;anchor=H12#H12\">",
"       \"Endotracheal tube management and complications\", section on 'Sinusitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important for a clinician to keep several things in mind when investigating a fever. First, clinicians should remain mindful that critically ill patients often have more than one infection. Second, evidence of infection and inflammation (eg, leukocytosis, pus) may be altered if the patient is immunosuppressed. And, finally, medical technologies (eg, continuous renal replacement therapy, extracorporeal membrane oxygenation [ECMO]) can modify or mask a fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of fever should be directed as its underlying cause, which is discussed in separate topic reviews.",
"   </p>",
"   <p>",
"    Perhaps the two most common clinical decisions that need to be made when a patient develops a new fever in the ICU are whether or not empiric antibiotic therapy is warranted and whether or not the patient&rsquo;s intravascular catheters need to be removed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effects of empiric antibiotics initiated for fever in a heterogeneous population of critically ill patients have not been studied. However, there is evidence in patients with suspected severe sepsis or septic shock that a shorter time to appropriate antibiotic administration is associated with lower mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/40,53\">",
"       40,53",
"      </a>",
"      ]. There is also evidence that appropriate antibiotic therapy dramatically reduces mortality among patients with neutropenia and fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/54\">",
"       54",
"      </a>",
"      ]. Infection of ventricular assist devices can be catastrophic, as device removal is often not possible without concurrent transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/55\">",
"       55",
"      </a>",
"      ]. On the basis of this evidence, we recommend that patients in the ICU who develop a new fever be treated with empiric antibiotics if they are deteriorating, in shock, neutropenic, or have a ventricular assist device. We also believe the empiric therapy is warranted for patients who have a temperature &ge;38.9&ordm;C (&ge;102&ordm;F) because most fevers in this range will be infectious. For most other patients, further diagnostic work-up with ongoing clinical assessment prior to the initiation of antibiotic therapy is reasonable.",
"     </li>",
"     <li>",
"      Whether or not to routinely remove an intravascular catheter (or other device) in a febrile patient is a controversial and evolving issue. Generally speaking, considerations in the decision include the severity of illness, age of the catheter, and probability that the catheter is the source of fever. The management of a catheter in the setting of possible intravascular catheter-related infections is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of intravascular catheter-related infections\", section on 'Catheter management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever itself does not generally require treatment with antipyretics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ) or external cooling (ie, cooling blanket, ice packs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/56-58\">",
"     56-58",
"    </a>",
"    ], and some evidence suggests that the use of antipyretics may worsen outcomes in sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/59\">",
"     59",
"    </a>",
"    ]. Exceptions to this are when the fever may be detrimental to the outcome (eg, increased intracranial pressure) or is &ge;41&ordm;C (&ge;105.8&ordm;F) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. If body temperature exceeds the &ldquo;critical thermal maximum&rdquo;, which is thought to be between 41.6&ordm;C and 42&ordm;C, life-threatening complications can ensue (eg, rhabdomyolysis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35576/abstract/62\">",
"     62",
"    </a>",
"    ]. The management of severe hyperthermia, including external cooling, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4139741\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal body temperature is approximately 37.0&ordm;C (98.6&ordm;F), although this varies with the time of day and the method of measurement used. We define a fever as a body temperature of 38.3&ordm;C (101&ordm;F) or higher. (See",
"      <a class=\"local\" href=\"#H22450950\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conventional means of measuring temperature in the ICU include intravascular, intravesicular (ie, bladder), rectal, and oral. The gold standard is the thermistor on a pulmonary artery catheter. Regardless of which method is chosen, the same method and site of measurement should be used repeatedly to facilitate the trending of serial measurements. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Temperature measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sources of fever in the ICU may be infectious (",
"      <a class=\"graphic graphic_table graphicRef73551 \" href=\"mobipreview.htm?5/51/5948\">",
"       table 1",
"      </a>",
"      ) or noninfectious (",
"      <a class=\"graphic graphic_table graphicRef68779 \" href=\"mobipreview.htm?21/63/22524\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A review of the medical history and a full physical examination should be performed whenever a patient develops an unexplained fever in the ICU. Blood cultures are the only mandatory diagnostic tests in patients with a new fever. Additional investigation is generally needed, but the exact tests that are indicated depend upon the clinical assessment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of fever should be directed as its underlying cause. Perhaps the two most common clinical decisions that need to be made when a patient develops a new fever in the ICU are whether empiric antibiotic therapy is warranted and whether the patient&rsquo;s intravenous catheters need to be removed (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For ICU patients with a new fever whose clinical condition is deteriorating, who are in shock, or who are neutropenic, we recommend the initiation of empiric antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For ICU patients with a new fever who have a ventricular assist device, we recommend the initiation of empiric antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For ICU patients with a new fever that is &ge;38.9&ordm;C (&ge;102&ordm;F), we suggest the initiation of empiric antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For most other ICU patients with a new fever, further diagnostic work-up with ongoing clinical assessment prior to the initiation of antibiotic therapy is warranted.",
"     </li>",
"     <li>",
"      The management of a catheter in the setting of a possible intravascular catheter-related infection is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of intravascular catheter-related infections\", section on 'Catheter management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever itself does not generally require treatment with antipyretics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ) or external cooling (ie, cooling blanket, ice packs). Exceptions to this are when the fever is impairing management (eg, increasing ventilatory requirements), may be detrimental to the outcome (eg, increased intracranial pressure), or &ge;41&ordm;C (&ge;105.8&ordm;F). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/1\">",
"      O'Grady NP, Barie PS, Bartlett JG, et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008; 36:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/2\">",
"      Fallis WM. Monitoring urinary bladder temperature in the intensive care unit: state of the science. Am J Crit Care 2002; 11:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/3\">",
"      Giuliano KK, Scott SS, Elliot S, Giuliano AJ. Temperature measurement in critically ill orally intubated adults: a comparison of pulmonary artery core, tympanic, and oral methods. Crit Care Med 1999; 27:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/4\">",
"      Schmitz T, Bair N, Falk M, Levine C. A comparison of five methods of temperature measurement in febrile intensive care patients. Am J Crit Care 1995; 4:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/5\">",
"      Klein DG, Mitchell C, Petrinec A, et al. A comparison of pulmonary artery, rectal, and tympanic membrane temperature measurement in the ICU. Heart Lung 1993; 22:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/6\">",
"      Nimah MM, Bshesh K, Callahan JD, Jacobs BR. Infrared tympanic thermometry in comparison with other temperature measurement techniques in febrile children. Pediatr Crit Care Med 2006; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/7\">",
"      Marik PE. Fever in the ICU. Chest 2000; 117:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/8\">",
"      Romano MJ, Fortenberry JD, Autrey E, et al. Infrared tympanic thermometry in the pediatric intensive care unit. Crit Care Med 1993; 21:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/9\">",
"      Robinson JL, Seal RF, Spady DW, Joffres MR. Comparison of esophageal, rectal, axillary, bladder, tympanic, and pulmonary artery temperatures in children. J Pediatr 1998; 133:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/10\">",
"      Lefrant JY, Muller L, de La Coussaye JE, et al. Temperature measurement in intensive care patients: comparison of urinary bladder, oesophageal, rectal, axillary, and inguinal methods versus pulmonary artery core method. Intensive Care Med 2003; 29:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/11\">",
"      Hebbar K, Fortenberry JD, Rogers K, et al. Comparison of temporal artery thermometer to standard temperature measurements in pediatric intensive care unit patients. Pediatr Crit Care Med 2005; 6:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/12\">",
"      Kimberger O, Cohen D, Illievich U, Lenhardt R. Temporal artery versus bladder thermometry during perioperative and intensive care unit monitoring. Anesth Analg 2007; 105:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/13\">",
"      Circiumaru B, Baldock G, Cohen J. A prospective study of fever in the intensive care unit. Intensive Care Med 1999; 25:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/14\">",
"      Laupland KB, Shahpori R, Kirkpatrick AW, et al. Occurrence and outcome of fever in critically ill adults. Crit Care Med 2008; 36:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/15\">",
"      Stocchetti N, Rossi S, Zanier ER, et al. Pyrexia in head-injured patients admitted to intensive care. Intensive Care Med 2002; 28:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/16\">",
"      Oliveira-Filho J, Ezzeddine MA, Segal AZ, et al. Fever in subarachnoid hemorrhage: relationship to vasospasm and outcome. Neurology 2001; 56:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/17\">",
"      Commichau C, Scarmeas N, Mayer SA. Risk factors for fever in the neurologic intensive care unit. Neurology 2003; 60:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/18\">",
"      Brisinda G, Maria G, Ferrante A, Civello IM. Evaluation of prognostic factors in patients with acute pancreatitis. Hepatogastroenterology 1999; 46:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/19\">",
"      Bohidar NP, Garg PK, Khanna S, Tandon RK. Incidence, etiology, and impact of Fever in patients with acute pancreatitis. Pancreatology 2003; 3:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/20\">",
"      Peres Bota D, Lopes Ferreira F, M&eacute;lot C, Vincent JL. Body temperature alterations in the critically ill. Intensive Care Med 2004; 30:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/21\">",
"      Reaven NL, Lovett JE, Funk SE. Brain injury and fever: hospital length of stay and cost outcomes. J Intensive Care Med 2009; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/22\">",
"      Cunha BA. Fever in the critical care unit. Crit Care Clin 1998; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/23\">",
"      Cunha BA. Fever in the intensive care unit. Intensive Care Med 1999; 25:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/24\">",
"      Lucet JC, Bouadma L, Zahar JR, et al. Infectious risk associated with arterial catheters compared with central venous catheters. Crit Care Med 2010; 38:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/25\">",
"      Eggimann P, Pittet D. Infection control in the ICU. Chest 2001; 120:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/26\">",
"      George DL, Falk PS, Umberto Meduri G, et al. Nosocomial sinusitis in patients in the medical intensive care unit: a prospective epidemiological study. Clin Infect Dis 1998; 27:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/27\">",
"      Holzapfel L, Chevret S, Madinier G, et al. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized, clinical trial. Crit Care Med 1993; 21:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/28\">",
"      Barie PS, Eachempati SR. Acute acalculous cholecystitis. Curr Gastroenterol Rep 2003; 5:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/29\">",
"      Kalliafas S, Ziegler DW, Flancbaum L, Choban PS. Acute acalculous cholecystitis: incidence, risk factors, diagnosis, and outcome. Am Surg 1998; 64:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/30\">",
"      Laurila J, Syrj&auml;l&auml; H, Laurila PA, et al. Acute acalculous cholecystitis in critically ill patients. Acta Anaesthesiol Scand 2004; 48:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/31\">",
"      Kaleya RN, Boley SJ. Acute mesenteric ischemia. Crit Care Clin 1995; 11:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/32\">",
"      Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001; 345:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/33\">",
"      Marik PE, Andrews L, Maini B. The incidence of deep venous thrombosis in ICU patients. Chest 1997; 111:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/34\">",
"      Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995; 274:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/35\">",
"      Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990; 263:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/36\">",
"      Stein PD, Afzal A, Henry JW, Villareal CG. Fever in acute pulmonary embolism. Chest 2000; 117:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/37\">",
"      Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 2002; 122:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/38\">",
"      Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/39\">",
"      Ringel MD. Management of hypothyroidism and hyperthyroidism in the intensive care unit. Crit Care Clin 2001; 17:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/40\">",
"      Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/41\">",
"      Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/42\">",
"      Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/43\">",
"      Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004; 190:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/44\">",
"      Marshall JC, Walker PM, Foster DM, et al. Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence. Crit Care 2002; 6:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/45\">",
"      P&oacute;voa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med 1998; 24:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/46\">",
"      M&uuml;ller B, Becker KL, Sch&auml;chinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/47\">",
"      Claeys R, Vinken S, Spapen H, et al. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002; 30:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/48\">",
"      Mackenzie I, Woodhouse J. C-reactive protein concentrations during bacteraemia: A comparison between patients with and without liver dysfunction. Intensive Care Med 2006; 32:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/49\">",
"      Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34:2596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/50\">",
"      Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003; 123:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/51\">",
"      van Zanten AR, Dixon JM, Nipshagen MD, et al. Hospital-acquired sinusitis is a common cause of fever of unknown origin in orotracheally intubated critically ill patients. Crit Care 2005; 9:R583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/52\">",
"      Vargas F, Bui HN, Boyer A, et al. Transnasal puncture based on echographic sinusitis evidence in mechanically ventilated patients with suspicion of nosocomial maxillary sinusitis. Intensive Care Med 2006; 32:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/53\">",
"      Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/54\">",
"      Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40 Suppl 4:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/55\">",
"      Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg 2010; 90:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/56\">",
"      Gozzoli V, Sch&ouml;ttker P, Suter PM, Ricou B. Is it worth treating fever in intensive care unit patients? Preliminary results from a randomized trial of the effect of external cooling. Arch Intern Med 2001; 161:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/57\">",
"      Ryan M, Levy MM. Clinical review: fever in intensive care unit patients. Crit Care 2003; 7:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/58\">",
"      Schulman CI, Namias N, Doherty J, et al. The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study. Surg Infect (Larchmt) 2005; 6:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/59\">",
"      Lee BH, Inui D, Suh GY, et al. Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: multi-centered prospective observational study. Crit Care 2012; 16:R33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/60\">",
"      Cairns CJ, Andrews PJ. Management of hyperthermia in traumatic brain injury. Curr Opin Crit Care 2002; 8:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/61\">",
"      Marion DW. Controlled normothermia in neurologic intensive care. Crit Care Med 2004; 32:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35576/abstract/62\">",
"      Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002; 346:1978.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1624 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35576=[""].join("\n");
var outline_f34_47_35576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4139741\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22450950\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TEMPERATURE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22451247\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infectious causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Noninfectious causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Noninfectious fever without shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Noninfectious fever with shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4139741\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/51/5948\" title=\"table 1\">",
"      Infectious causes fever ICU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/63/22524\" title=\"table 2\">",
"      Noninfectious causes fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/14/2284\" title=\"table 3\">",
"      Risk acalculous cholecystitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6742?source=related_link\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/51/26424?source=related_link\">",
"      Arterial catheterization techniques for invasive monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/10/8361?source=related_link\">",
"      Pathophysiology and treatment of fever in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33655?source=related_link\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_47_35577="Management of the infant with ambiguous genitalia";
var content_f34_47_35577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the infant with ambiguous genitalia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Christopher P Houk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Lynne L Levitsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35577/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/47/35577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with a congenital discrepancy between external genitalia and gonadal and chromosomal sex are classified as having a disorder of sex development (DSD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/1\">",
"     1",
"    </a>",
"    ]. Many of these individuals present as newborns with an atypical genital appearance often termed \"ambiguous genitalia\". The birth of an infant with ambiguous genitalia presents a unique set of challenging management issues.",
"   </p>",
"   <p>",
"    Psychosexual development is influenced by multiple factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genes involved in sexual development",
"     </li>",
"     <li>",
"      Gender differences in brain structure",
"     </li>",
"     <li>",
"      Prenatal androgen exposure",
"     </li>",
"     <li>",
"      Societal and cultural factors",
"     </li>",
"     <li>",
"      Family dynamics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased appreciation of the complexity of these factors and their interactions has led many experts to question the wisdom of previous management paradigms that promoted irreversible genital surgery, with sex assignment based on potential for reproduction and traditional sexual function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In addition, more long-term outcome data are now available to provide insight into appropriate early management decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of infants with DSDs, which is critical and often controversial in the absence of well-defined outcome-based guidelines, will be discussed here. The evaluation of these infants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link\">",
"     \"Evaluation of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL STABILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial stabilization of infants with a DSD requires attention to both medical and psychosocial issues. The urgent medical issue is the possibility of adrenal crisis in infants with the salt-wasting form of congenital adrenal hyperplasia (CAH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fluid and electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital adrenal hyperplasia is the most common cause of 46,XX DSD (virilization) and one of many causes of 46,XY DSD (undervirilization). If CAH is not treated, hypoglycemia and symptoms of salt-wasting can occur within the first few days to weeks of life, including vomiting, diarrhea, hypovolemia, hyponatremia with or without hyperkalemia, and cardiovascular collapse (",
"    <a class=\"graphic graphic_table graphicRef76865 \" href=\"mobipreview.htm?39/0/39949\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/9\">",
"     9",
"    </a>",
"    ]. A rapid overview guiding the recognition and treatment of adrenal crisis is shown in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef61357 \" href=\"mobipreview.htm?22/54/23405\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Management in neonates'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    As soon as CAH is suspected, a sample of blood should be obtained for confirmatory steroid hormone measurements (most importantly, 17-OH progesterone), serum and urine electrolytes, should be measured, and a karyotype performed. &nbsp;",
"   </p>",
"   <p>",
"    Infants with genital ambiguity and nonpalpable gonads should be presumed to have CAH and observed for salt-loss until the diagnosis is confirmed or excluded. After the confirmatory blood sample is obtained, serum and urine electrolytes should be monitored daily, and more often if there are abnormal findings. Hyperkalemia is usually the first sign of impending adrenal crisis in infants with salt-wasting, but a shift to increased urinary excretion of sodium compared with potassium can provide early warning. If any electrolyte abnormalities are detected (and before significant hyponatremia or hyperkalemia develops), treatment doses of glucocorticoid and mineralocorticoid should be initiated, to prevent the potentially life-threatening manifestations of adrenal crisis. An initial dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    50 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    should be administered as an IV bolus (a typical neonatal dose is 25 mg), followed by hydrocortisone 50 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV per day as a continuous infusion, or divided every six hours. These stress doses of hydrocortisone should be continued until the patient is stable and feeding normally, or until the possibility of CAH is excluded. There is no parenteral preparation of mineralocorticoid, but hydrocortisone has adequate mineralocorticoid effect at these doses to make mineralocorticoid supplementation unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Management in neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If stress-dose glucocorticoids are administered before the critical sample for measurement of various precursor steroids is obtained, the levels of precursor steroids will usually remain high enough that a diagnosis can still be made within the first 24 to 48 hours. If not, it may be necessary to perform a stimulation test with adrenocorticotrophic hormone (ACTH) to establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24726?source=see_link\">",
"     \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    When symptoms and signs of adrenal crisis are present (hypoglycemia, hypovolemia, hyponatremia, and hyperkalemia, with or without vomiting and diarrhea), fluids and electrolytes should be replaced urgently.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intravenous bolus of 10 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of normal saline should be administered. Hypotonic saline",
"      <strong>",
"       should not be used",
"      </strong>",
"      because it can worsen the hyponatremia.",
"     </li>",
"     <li>",
"      An intravenous bolus of 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of 10 percent dextrose should be considered if there is significant hypoglycemia.",
"     </li>",
"     <li>",
"      Hyperkalemia should be corrected with the administration of glucose and insulin if necessary. However, usually treatment with saline and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      rapidly reverses hyperkalemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Family coping",
"    </span>",
"    &nbsp;&mdash;&nbsp;The birth of an infant with ambiguous genitalia is a psychosocial emergency for the family. An appropriate therapeutic plan can be developed only with the full participation of the parents, after a careful and complete evaluation by an experienced team of endocrinologists, geneticists, and surgeons, aided by individuals capable of sophisticated psychosocial support. Even with optimal education and support, the parents and family may need some time to adjust to the diagnosis before they are capable of making decisions regarding management. &nbsp;",
"   </p>",
"   <p>",
"    In these discussions, the emphasis should be on helping the parents understand that genital ambiguity, although uncommon, is biologically understandable (eg, normal but atypical) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/10\">",
"     10",
"    </a>",
"    ]. In general, we talk with the family about the genitalia not being fully formed or being overly developed and discuss the embryology of the indeterminate external genitalia in utero, followed by successive maturation toward male or female typical genitals. This discussion should be targeted to meet the intellectual and emotional capacity of the family, and special needs caused by the family's cultural or religious background should be identified and addressed.",
"   </p>",
"   <p>",
"    For practical purposes, we suggest that until the family is sure about gender assignment, no birth announcements describing gender be distributed. Similarly, the birth certificate should not be completed until the diagnosis and gender of rearing are determined. If the diagnosis is clear (eg, mild virilization in a girl with 21-hydroxylase deficiency) then the family can comfortably announce gender. If the diagnosis will be delayed several days by testing, the family will require sensitive counseling to be able to postpone the announcement about gender of the newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most families, even the most sophisticated, immediately feel guilty that they are in some way responsible for the genital malformation. This must be discussed openly; the discussion will differ depending upon the nature of the disorder. If the child is known to have a gene defect, the defect and its manifestations must be described so that the family can cope with the disorder as it is currently understood.",
"   </p>",
"   <p>",
"    Families of children with genital ambiguity often wish to discuss issues of long-term reproductive function and sexuality early in the evaluation. These issues should be discussed in a frank and open way; discussion should be facilitated by appropriate members of the healthcare team, within the limits of family understanding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial stabilization, infants with DSDs should be thoroughly evaluated to identify the type of DSD, because this information will be an important guide for management. The types of DSD and steps in the evaluation are discussed in detail separately. The infant should also be evaluated for renal dysfunction and other nongenital abnormalities that might suggest a syndromic form of DSD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of the infant with ambiguous genitalia\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the complexity of DSD diagnoses and the infrequency with which they are seen, all affected infants should be evaluated and managed at centers with experienced DSD teams, if possible. If transfer or evaluation at a DSD center is unavailable, consultation should be sought with a DSD team to help organize and facilitate management. In response to the consensus conference on the management of DSD in 2006, several groups have published useful information on the development of collaborative management teams and reviewed progress in implementing such multidisciplinary teams in Western Europe and in North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENDER DECISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for and timing of genital reconstruction is controversial and evolving. An evidence-based approach is hampered by the lack of adequately sized studies of long-term outcomes. Consequently, much of what is known about adult adaptation and satisfaction comes from anecdotal reports of highly publicized cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. A series of 166 children with disorder of sex development (DSD) aged 4 to 12 suggests that androgens play a decisive role in gender role behaviors but also confirms the observations of other investigators that gender identity is most commonly predicted by the gender of rearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most DSDs, outcomes in adulthood can be predicted with a reasonable degree of confidence (",
"    <a class=\"graphic graphic_table graphicRef57610 \" href=\"mobipreview.htm?40/57/41884\">",
"     table 3",
"    </a>",
"    ). For some patients, particularly those with severely virilized 46,XX DSD and severely undervirilized 46,XY DSD, the outcomes can be difficult to predict, presenting a challenge to contemporary medical management. Although prenatal androgen exposure may influence gender-related behavior, it does not always predict gender identity or sexual orientation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/16\">",
"     16",
"    </a>",
"    ]. For some types of DSD in which adult psychosexual outcome is particularly uncertain, some centers that treat infants with ambiguous genitalia are shifting away from the traditional approach of recommending genital reconstruction in early infancy, and now favor postponing this intervention until the individual patient can participate in decision-making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Traditional approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach assumed that decisions for early surgery would make life easier in many ways for young children with DSDs, as well as for their parents and caregivers, and that gender identity would follow from gender assignment and sex of rearing. This approach was based upon the following three assumptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gender identity is imposable (ie, it is the product of gender assignment and rearing).",
"     </li>",
"     <li>",
"      Maintaining the potential for fertility is the primary goal in XX infants, followed closely by sexual function and cosmesis; maintaining the potential for adequate sexual function is the primary goal in XY infants.",
"     </li>",
"     <li>",
"      Adequate cosmetic result will lead to adult adaptation and satisfaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this approach, externally virilized XX infants with CAH would be assigned a female sex and undergo staged genital reconstruction during infancy, thus potentially preserving fertility. XY patients with \"inadequate phallic development\" also would be assigned a female sex and undergo staged genital reconstruction during infancy to satisfy the goal of passive sexual function and cosmetic appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/19\">",
"     19",
"    </a>",
"    ]. These decisions often hinged on whether construction of a penile urethra appeared feasible to the pediatric urologist.",
"   </p>",
"   <p>",
"    This traditional approach was restated in the 2000 Policy Statement of the American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/20\">",
"     20",
"    </a>",
"    ]. However, a more recent consensus conference argues for a less rigid reinterpretation of this approach, identifying several important limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach has several problems, most of which involve the lack of supportive evidence from long-term follow-up studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is little evidence to support the contention that initial gender assignment is more effective if linked to early genital surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/6\">",
"       6",
"      </a>",
"      ]. Early genital surgery has been particularly criticized by patient advocacy groups.",
"     </li>",
"     <li>",
"      There is little evidence to support the contention that the appearance of the external genitalia governs gender role decisions in adulthood, whereas data to the contrary are beginning to emerge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/21\">",
"       21",
"      </a>",
"      ]. Thus, endogenous gender identity may be discordant with the appearance of the external genitalia.",
"     </li>",
"     <li>",
"      There is little evidence to support a link between early genital surgery and gender identity or psychosexual orientation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is clear that, at least for some patients, irreversible genital reconstruction may complicate the lives of adults with these disorders. The most vocal adult individuals with ambiguous genitalia advocate for the delay of all unnecessary surgical intervention until an informed decision can be made by the individual patient. Whether most affected adults concur with this opinion is not known. In many cases, it is impossible to predict the relationship between sex",
"    <span class=\"nowrap\">",
"     assignment/rearing",
"    </span>",
"    and ultimate gender identity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/2-4,22,23\">",
"     2-4,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Well-designed studies of patient outcomes comparing the traditional surgically oriented approach to less invasive management are needed. A",
"    <a class=\"external\" href=\"file://www.eurodsd.eu/\">",
"     DSD data registry",
"    </a>",
"    has been developed in Europe to facilitate such studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;  &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Follow-up studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies with long-term follow-up and evaluation have been published. When considering these studies, it is important to remember that the reported outcomes do not reflect current surgical techniques and advances. In addition, advocacy groups have suggested that reported outcomes may be overly optimistic because the most discontented adult individuals born with DSDs often decline to participate in such studies. It is also possible that patients who have done well may not want to be subjected to additional evaluation. These types of recruitment imbalances may bias the studies toward overly optimistic or overly pessimistic outcomes. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Functional and cosmetic outcomes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 33 adolescent patients who had feminizing surgery for ambiguous genitalia (21 with CAH, 12 with miscellaneous conditions) or abnormalities of cloacal or urogenital development (11 patients), 41 percent had poor cosmetic outcome as judged by a surgical team; 89 percent required additional major surgery; and 39 percent had clitoral regrowth, requiring additional surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, the authors suggest that sexual function is impaired in those patients who underwent clitoral recession. These data, although far from conclusive, suggest most patients require multiple surgeries and raise the question of whether good cosmetic outcome is attainable in a majority of patients.",
"     </li>",
"     <li>",
"      In another study of 28 patients who were raised as females (18 with and 10 without a history of clitoral surgery), the rates of non-sensuality and inability to achieve orgasm were higher in the clitoral surgery group (78 and 39 percent versus 20 and 0 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/25\">",
"       25",
"      </a>",
"      ]. This study suggests that sexual dysfunction is common among women who underwent clitoral surgery as infants or children. Another large study of women with DSD noted that feminizing surgery itself might not worsen outcomes, but the women as a group had tremendous psychological distress and sexual dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/6\">",
"       6",
"      </a>",
"      ]. In general, these women had not received adequate medical-psychological supports.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The skill of surgeons performing these procedures in newborns on a routine basis and the techniques used to ensure cosmetic and functional outcome have undoubtedly improved since the women in the studies described above were treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Nonetheless, the outcome of treatment remains problematic, particularly when one considers that genital reconstructive surgery requires the removal of tissue that may be necessary for alternative gender reconstruction if the patient desires it as an adult. In addition, surgical reconstruction of the penis has improved, making concerns about adequacy of male reconstruction less pertinent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/28\">",
"     28",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Psychosocial outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from several observational studies suggests that individuals with 46,XY DSD have high rates of dissatisfaction with their surgical repairs and their adult sex lives, but the reported rate of dissatisfaction varies among studies.",
"   </p>",
"   <p>",
"    A comprehensive study reported long-term psychosocial outcomes with gender assignments made using traditional approaches in individuals with an XY karyotype and a DSD. Thirty-nine XY patients with genital ambiguity as infants or children with various diagnoses (including partial androgen insensitivity syndrome [PAIS] and partial gonadal dysgenesis [PGD]) were followed into adulthood; 21 were living as men and 18 as women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/29\">",
"     29",
"    </a>",
"    ]. The groups did not differ in degree of satisfaction with physical appearance, genital function, or sex of rearing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 21 individuals assigned male gender, 16 were mainly satisfied with a male sex of rearing, and five were dissatisfied. One individual considered himself intersex and one underwent gender reassignment as a female. Approximately 85 percent had exclusively heterosexual interests. Multiple surgeries were required for phallic reconstruction in all male patients (at least 2 and sometimes more than 10).",
"     </li>",
"     <li>",
"      Among the 18 individuals assigned female gender, 14 were satisfied with their female sex of rearing and 4 were dissatisfied. One functioned unhappily with a female homosexual orientation, one underwent gender reassignment as a male, and seven had exclusively heterosexual interests. Fewer surgeries for genital reconstruction were required in patients who were feminized (between one and three).",
"     </li>",
"     <li>",
"      In a companion paper, this group examined patient knowledge and information [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/30\">",
"       30",
"      </a>",
"      ]. Of 96 eligible patients with an XY chromosomal constitution with normal female genitalia or genital ambiguity, 51 were living as women and 45 as men. More than one-half felt they did not have adequate information about their medical histories or diagnoses. &nbsp;",
"      <br/>",
"      <br/>",
"      The authors of these two studies concluded that a 46,XY chromosome complement with weak prenatal androgen exposure is not sufficient to determine sexual identity and that either gender assignment leads to equal degrees of life happiness and unhappiness. The authors suggest a process of education, re-education, and psychological support, so that individuals with these difficult problems do not feel deprived of information or counseling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies suggest higher rates of dissatisfaction among individuals with 46,XY DSD. In a study of 57 German adults with various types of XY DSD, a large number of individuals were markedly dissatisfied with their surgical repairs and adult sex lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/5\">",
"     5",
"    </a>",
"    ]. Among the group characterized as partially androgenized females, about 41 percent were dissatisfied with their sex life, as compared with 11 percent among 46,XX controls, and 47 percent were dissatisfied with the functional result of their surgery. The authors of this study suggest delaying reconstructive genital surgery until the patient is mature enough to participate in the decision process and increasing the amount of psychological supports available for these children and their families. However, 46,XY DSD individuals raised as males also have a burden of morphologic and functional differences related to relative adult short stature and persistent microphallus which may influence quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that some of the differences in outcomes are determined by the type of DSD. In particular, it appears that individuals with an XY karyotype and congenital defects affecting the genitalia, but who can potentially virilize during puberty or with androgen treatment, do not easily accept female gender assignment. Examples include children with 17-beta-hydroxysteroid dehydrogenase 3 deficiency, 5-alpha-reductase deficiency, micropenis, and bladder exstrophy. Case reports and other studies suggest that female gender assignment in these children is often problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The reason for this apparent difference in outcomes is not entirely clear, but may be due to differences in prenatal androgen exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link&amp;anchor=H28#H28\">",
"     \"Evaluation of the infant with ambiguous genitalia\", section on 'Abnormal androgen synthesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30423?source=see_link\">",
"     \"Steroid 5-alpha-reductase 2 deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11849?source=see_link&amp;anchor=H9#H9\">",
"     \"Surgical management and postoperative outcome of children with bladder exstrophy\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Current approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, gender assignment in infants with ambiguous genitalia is difficult, controversial, and evolving. The rare infants with an XX karyotype and virilization with a complete penile urethra (Prader V virilization) secondary to CAH pose a particularly difficult problem; most, but not all of these individuals identify as females in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/34\">",
"     34",
"    </a>",
"    ]. Recommended approaches are available from several groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Consensus statement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Consensus Statement on the Management of Intersex Disorders developed by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Research was published in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/35\">",
"     35",
"    </a>",
"    ]. This report represents a consensus of experts in DSDs in Europe and North America, and may not represent the views or special needs of patients or providers in other cultures. This report suggests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All virilized 46,XX children with CAH, even those with normal-appearing male external genitalia, should be raised in the female role given that more than 90 percent of these patients identify as females in adulthood. Surgery should be reserved for those with severe virilization (Prader III, IV, V) (",
"      <a class=\"graphic graphic_figure graphicRef73502 graphicRef52525 \" href=\"mobipreview.htm?13/34/13863\">",
"       figure 1A-B",
"      </a>",
"      ) and anatomically-based clitoral reduction should be performed in conjunction with repair of the common urogenital sinus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Modest clitoral hypertrophy should not be surgically treated until the patient is able to make a mature decision about this. However, early vaginoplasty and separation of the vagina and urethra is recommended because of the potential beneficial effects of estrogen on tissue in early infancy and avoidance of urinary tract infections and other urinary tract complications caused by the urogenital sinus.",
"     </li>",
"     <li>",
"      In children with a high proximal junction (confluence) between the vagina and urethra, early vaginoplasty and clitoroplasty is an appropriate choice if it can be performed at a center with large experience.",
"     </li>",
"     <li>",
"      For fully masculinized individuals with an XX karyotype who are identified later in life, the decision to reassign gender should be initiated by the patient and include careful consultation and psychological evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Alternative guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative point of view has been expressed by others who have studied the outcomes of gender assignment and early surgical correction in older individuals. In another set of published guidelines for managing persons with ambiguous genitalia, gender assignment is separated from genital surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/10\">",
"     10",
"    </a>",
"    ]. This approach suggests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with disorders that are expected to lead to endogenous virilization at the time of puberty should be raised as males. This includes individuals with an XY karyotype, relative virilization of the genitalia, and either partial androgen insensitivity syndrome (PAIS), 5-alpha-reductase deficiency, or 17-beta hydroxysteroid dehydrogenase type 3 deficiency. This approach should also be strongly considered in XX individuals with CAH and a penile urethra.",
"     </li>",
"     <li>",
"      Children with female-typical genitalia should be raised in the female gender. This includes some 46,XY individuals with poorly virilized genitalia and either PAIS or gonadal dysgenesis. It also includes some 46,XX individuals with CAH with milder degrees of virilization.",
"     </li>",
"     <li>",
"      No surgery should be performed for cosmetic reasons alone until the individual with a DSD is capable of making the decision for surgery autonomously. The optimal process probably includes shared decision-making between the patient, caregivers and health care providers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/36\">",
"       36",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Parents and caretakers should reinforce the chosen gender role, but also be open to and uncritical if the child displays interest in an alternate gender role.",
"     </li>",
"     <li>",
"      Psychological counseling should be provided for parents to ensure their understanding of the necessity for individualized decision-making that is unique to the underlying DSD, the child's phenotype, and the social circumstance. These decisions will also be influenced by preferences within families based on cultural understanding and requirements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our experience is that gender identity decisions are difficult for many individuals with ambiguous genitalia and that gender role behavior and sexual identity may not be fixed until the individuals are young adults. Epidemiologists studying gender behaviors in young children without DSDs report that up to 5 percent sometimes or frequently wish to be the opposite sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, those individuals with DSDs who have had early surgical genital correction and later desire gender reassignment from female to male, are rightfully angry about the loss of genital tissue that makes such reassignment anatomically difficult. These observations support the idea that surgery for cosmetic reasons alone should be postponed until the DSD individual&rsquo;s sexual identity is firmly established and there is capacity to make a mature and autonomous decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Gender assignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We propose, in accord with available data, that gender assignment and sex of rearing should be based upon the most probable adult gender identity and potential for adult function (",
"    <a class=\"graphic graphic_table graphicRef57610 \" href=\"mobipreview.htm?40/57/41884\">",
"     table 3",
"    </a>",
"    ). Factors to be considered in this decision include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosis",
"     </li>",
"     <li>",
"      Degree of virilization as a marker of prenatal androgen exposure",
"     </li>",
"     <li>",
"      Capacity to respond to exogenous androgen",
"     </li>",
"     <li>",
"      Potential for adult sexual",
"      <span class=\"nowrap\">",
"       function/fertility",
"      </span>",
"     </li>",
"     <li>",
"      Parents' socio-cultural background and expectations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relevance of these factors is supported by an increasing number of studies examining gender identity and sexual orientation in a variety of DSDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Decisions about sex of rearing should only be made by an informed family after careful evaluation, documentation, and consultation. This decision should be made as soon as the necessary diagnostic information can be collected, usually within a few days after birth. The child should be raised in the predicted gender role, but should be an active participant in the long-term gender decisions during childhood and adolescence.",
"   </p>",
"   <p>",
"    We concur with the alternative guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/10\">",
"     10",
"    </a>",
"    ] about the choice of sex of rearing for children with an XY chromosomal makeup: In most cases (other than complete androgen insensitivity syndrome and complete gonadal dysgenesis), these individuals should be raised as males, and any surgery that is for cosmetic reasons alone should be deferred until the individual is capable of participating in the decision for surgery (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Genital surgery'",
"    </a>",
"    below). Counseling should include the concept that gender identity may change as the child grows. Although we suggest this recommendation be made to the family, we recognize the family will bear the major burden of rearing a \"different-looking child.\" For this reason, the family should make the decisions regarding sex of rearing and timing of surgery, and should be supported in their decision after appropriate counseling.",
"   </p>",
"   <p>",
"    Rarely, an XX child with CAH will present with a complete penile urethra (Prader V). Such cases present a particularly difficult management issue. These children are the most technically difficult to reconstruct as females and probably the most likely to be more comfortable with a male gender designation. Therefore, differing from the Consensus Statement guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/35\">",
"     35",
"    </a>",
"    ], we think that in those rare 46,XX infants with essentially normal male external genitalia, consideration should be given to a male sex assignment if their families concur, particularly when the diagnosis is delayed. There are certainly many 46,XX individuals with severe neonatal masculinization who have had early surgery and made successful female life adjustments. However, there are also those who are unhappy with the surgical results, particularly those difficult cases requiring complex or repeated surgeries which interfered with female sexual functioning. Outcome data for such individuals suggest that when the diagnosis is delayed and the child is raised in a male role without androgen suppression, gender identity may gradually evolve from female to male [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Genital surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;We support an intermediate approach that relies heavily on available outcome evidence and surgical experience, yet supports the concept of individual autonomy for the individual with a DSD.",
"   </p>",
"   <p>",
"    There are no data demonstrating a link between early genital surgery and psychosexual orientation. Decisions for early surgery make life easier in many ways for the parents and caretakers and for young affected children. However, these irrevocable decisions may complicate the lives of adults with these disorders.",
"   </p>",
"   <p>",
"    Therefore, we suggest the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial gender assignment is female, consideration should be given to delaying clitoral surgery. By contrast, proceeding with vaginoplasty in infancy is acceptable because of the potential for improved functional outcome in the adult when surgeries are performed in young children.",
"     </li>",
"     <li>",
"      If the initial gender assignment is male, phallic reconstruction can be carried out in a time frame acceptable to the experienced surgeon performing the reconstruction. Such surgery will not irrevocably alter later gender decisions on the part of the adult patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although preservation of fertility is important, successful adult psychosexual adaptation and satisfaction are probably more important to most individuals. Therefore, a delay of clitoroplasty should be considered until the patient, with expert psychiatric guidance, can fully participate in the decision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/2\">",
"     2",
"    </a>",
"    ]. Indeed, for some infants with modest virilization, the clitoromegaly may become less problematic as the children grow and control of the congenital adrenal hyperplasia improves. Surgical recession may prove unnecessary.",
"   </p>",
"   <p>",
"    Further surgery, including revision vaginoplasty in young adulthood if requested by the patient, will be important for most of these girls if they assume a heterosexual lifestyle. If surgical intervention is deemed necessary at any point in the life of an individual, only the most skilled and experienced of surgeons should perform the necessary reconstructive procedures. The goal of surgery should be based on functional rather than cosmetic outcome, and care should be taken to spare the neurovascular supply of the genitalia.",
"   </p>",
"   <p>",
"    These suggestions must be carefully discussed with the family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/26,35\">",
"     26,35",
"    </a>",
"    ]. Whether the family chooses delayed reconstruction or early reconstruction, active participation and fully informed decision-making is required, and the family will need frequent psychosocial and medical support as the child grows to adulthood. The family should be fully informed about the estimated malignancy risk of the gonads and the need for monitoring if these are left in place (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Gonads'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There may be occasions when a decision for early surgery is made by the family despite these considerations. In this situation, the same emotional and medical support structure should be available to family and child. Sensitive and age-appropriate sharing of information with the child also is an important part of either management approach. Full disclosure of information to children, within their capacity to understand, is ethically necessary and enhances their ability to participate in decisions.",
"   </p>",
"   <p>",
"    Decisions about surgical management of the gonads, including considerations of malignant potential and fertility, are discussed below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Gonads'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term care of children born with a DSD requires attention to both psychosexual and medical concerns. Transition to adult care at the appropriate age is often problematic, and a coordinated program for such transition is as important, as in other chronic illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Psychosexual issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unlikely that psychosexual identity can be \"assigned\" as readily as the traditional model suggests. However, to the extent that it is possible, sex of rearing should be congruent with anticipated psychosexual identity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/10\">",
"     10",
"    </a>",
"    ]. This strategy is in the best interest of the child, given the cultural constraints of raising a child who has a DSD.",
"   </p>",
"   <p>",
"    Children with anatomic genital ambiguity who do not undergo early correction provide continued and various management issues for their parents. Once gender is assigned, the child should be raised in the predicted gender, although the parents must be flexible if the child makes a different gender decision, either verbally or through behaviors. Parents should be aware of this possibility and reminded of it as the child gets older and has a better understanding of his or her condition. A multidisciplinary team specializing in DSDs can facilitate the child's participation in any decision-making process, as appropriate to the child's age.",
"   </p>",
"   <p>",
"    For both the child and parents, long-term follow-up with mental health workers skilled in this area is critical to improved outcome. Counseling should be multi-staged and take place at birth, sometime after two years of age, at school entry, before and during pubertal changes, and annually during adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/10\">",
"     10",
"    </a>",
"    ]. Counseling should be detailed and honest. Pubertal development, the likelihood (or not) of menses and fertility, and sexual function should be addressed.",
"   </p>",
"   <p>",
"    Psychological gender must be monitored by skilled professionals during childhood, adolescence, and adulthood so that if initial decision-making proves inappropriate, the patient can receive full psychological, medical, and surgical support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medical concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing medical concerns in children with DSDs include the potential for malignancy in gonadal tissue or kidneys, the effects of altered levels of sex steroid exposure, and decreased bone mineral density. As an example, individuals with XY chromosomes and gonadal dysgenesis caused by WT-1 mutations may have Denys-Drash syndrome, which includes progressive renal disease and Wilms' tumor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link\">",
"     \"Evaluation of the infant with ambiguous genitalia\"",
"    </a>",
"    .) Other DSDs are associated with variable risks for gonadal malignancy, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gonads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gonadal tissue of infants who have a DSD may require specific management to decrease the risk of long-term complications such as cancer, torsion, and infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19037640\">",
"    <span class=\"h4\">",
"     Gonadectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal gonads bearing Y chromosomal material should be either brought into the scrotum where they can be monitored or removed surgically. The optimal age for performing this surgery varies based on the malignancy risk for the specific DSD. The risk for gonadal malignancy varies with the diagnosis and is summarized in the Consensus Statement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/35,44,45\">",
"     35,44,45",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    As an example, patients with mixed and XY gonadal dysgenesis have an increased risk of gonadal malignancy (&gt;30 percent in some series). Gonadectomy should be performed within the first decade of life in these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=see_link&amp;anchor=H25#H25\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Mixed GCT and SCST'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In contrast to the dysgenetic gonads seen in most other patients with DSDs, the risk of gonadal malignancy in patients with androgen insensitivity is minimal until late puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Delaying gonadectomy until after puberty may permit a relatively \"natural\" female puberty and greater bone density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this must be weighed against the slightly increased risk of malignancy and the potential psychological benefit of removing gonads that are in conflict with the sex of rearing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19037647\">",
"    <span class=\"h4\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular abdominal ultrasonography or MRI, with testicular palpation, should be performed in all patients with DSDs, who have abdominal or scrotal testes, respectively. Children with androgen insensitivity whose families decide to leave gonads in place through puberty should be monitored regularly; in our practice we perform ultrasound or MRI at least annually beginning at approximately 10 years of age. Children with gonadal dysgenesis should have screening at least every six months with ultrasound or MRI, starting at two to three years of age and continuing until gonadectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Sex steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with DSDs are often exposed to altered levels of sex steroids during childhood and adolescence. Sex steroid replacement should be conducted in a manner consistent with the sex of rearing and age of the child. The long-term sequelae of sex steroid deficiencies or end-organ unresponsiveness to sex steroid on bone mineral density and lipids must be considered. Bone mineral density and physical growth and development may be adversely affected by diminished sex steroid secretion during puberty. Height and weight should be monitored regularly and bone mineral density should be measured at puberty and then every two years depending upon the normality of the findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with XY gonadal dysgenesis and possible Denys-Drash syndrome require careful observation for the development of renal failure and Wilms tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35577/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=see_link&amp;anchor=H15#H15\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'Diffuse mesangial sclerosis with Drash syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUPPORT GROUPS AND INTERNET SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many individuals with DSDs and their families derive benefit from general or disease-oriented support groups. The following sites have been helpful to our patients and their families:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accord Alliance (formerly known as the Intersex Society of North America) (",
"      <a class=\"external\" href=\"file://www.accordalliance.org/\">",
"       www.accordalliance.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      DSD guidelines, a handbook for parents and clinical guidelines for providers, published by the Accord Alliance (",
"      <a class=\"external\" href=\"file://www.dsdguidelines.org/\">",
"       www.dsdguidelines.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bodies Like Ours (",
"      <a class=\"external\" href=\"file://www.bodieslikeours.org/forums\">",
"       www.bodieslikeours.org/forums",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Magic Foundation (",
"      <a class=\"external\" href=\"file://www.magicfoundation.org/\">",
"       www.magicfoundation.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toronto Hospital for Sick Children, patient information on sex development (",
"      <a class=\"external\" href=\"file://www.aboutkidshealth.ca/EN/HOWTHEBODYWORKS/Pages/default.aspx\">",
"       www.aboutkidshealth.ca/EN/HOWTHEBODYWORKS/Pages/default.aspx",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      CARES Foundation: information and support about congenital adrenal hyperplasia (",
"      <a class=\"external\" href=\"file://www.caresfoundation.org/productcart/pc/index.html\">",
"       www.caresfoundation.org/productcart/pc/index.html",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with a congenital discrepancy between external genitalia and gonadal and chromosomal sex are classified as having a disorder of sex development (DSD). Some DSDs present with a genital appearance that does not permit prompt gender declaration at birth, and this physical appearance is termed ambiguous genitalia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urgent medical issue is the possibility of adrenal crisis in infants with the salt-wasting form of congenital adrenal hyperplasia (CAH). The following should be performed urgently as soon as the possibility of CAH is suspected: (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial stabilization'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A sample of blood should be obtained for steroid hormone measurements (most importantly, 17-OH progesterone), and serum and urine electrolytes should be measured (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fluid and electrolytes'",
"      </a>",
"      above.). The first steps to determine the cause of the DSD are typically performed at the same time, and should include a karyotype and fluorescence in-situ hybridization (FISH) for the sex-determining region on the Y chromosome (SRY). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=see_link\">",
"       \"Evaluation of the infant with ambiguous genitalia\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      should be initiated if electrolyte abnormalities are present, and continued until the results of the adrenal testing are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If signs or symptoms of adrenal insufficiency are present (hypoglycemia, hypovolemia, hyponatremia, with or without hyperkalemia, with or without vomiting and diarrhea), fluids and electrolytes should be replaced urgently, using normal saline with supplemental dextrose, if needed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fluid and electrolytes'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      The birth of an infant with ambiguous genitalia is often confusing and highly distressing for the family, and prompt communication and psychosocial support is imperative. An appropriate therapeutic plan can only be developed with the full participation of the family, after a careful and complete evaluation by an experienced team of endocrinologists, geneticists, and surgeons, aided by individuals capable of sophisticated psychosocial support. Referral to a specialized center for children with DSD is strongly encouraged. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Family coping'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Gender assignment and surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decisions about gender assignment and surgery in patients with DSDs are complicated by societal and family expectations, the variability of phenotype, the uncertainty of adult gender identity, and by the lack of adequately sized studies of long-term outcomes.",
"     </li>",
"     <li>",
"      We base our advice on gender assignment and sex of rearing on the most probable adult gender identity and potential for adult function (",
"      <a class=\"graphic graphic_table graphicRef57610 \" href=\"mobipreview.htm?40/57/41884\">",
"       table 3",
"      </a>",
"      ). We suggest that the following advice be provided to families, in the context of a detailed discussion of their child's individual characteristics and risks, and respecting and supporting the family's own values and preferences. In each case, we suggest that the child be raised in the predicted gender role, but should be an active participant in the long-term gender decisions during childhood and adolescence (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Gender assignment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with complete androgen insensitivity syndrome do not have ambiguous genitalia and should be raised as females.",
"     </li>",
"     <li>",
"      Most 46,XX children with CAH should be raised as females. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Consensus statement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      46,XX infants who have essentially normal male external genitalia present a challenge because the ultimate gender identification of these individuals varies. Providers and families should consider raising these children in a male gender role. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Gender assignment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decisions about genital surgery should respect individual autonomy for the individual with a DSD wherever practicable, combined with practical considerations about surgical techniques and outcomes. We generally provide the following advice to families (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Genital surgery'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the initial gender assignment is female, we suggest delaying clitoral surgery, with a goal of waiting until the child expresses gender identity and can participate autonomously in the decision for surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). By contrast, we suggest proceeding with vaginoplasty in infancy because of the potential for improved functional outcome in the adult (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the initial gender assignment is male, phallic reconstruction can be carried out in a time frame acceptable to the experienced surgeon performing the reconstruction. Such surgery will not irrevocably alter later gender decisions on the part of the adult patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that surgery for cosmetic reasons alone be deferred until the individual is capable of participating in the decision for surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Long-term issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with DSDs and their families should be offered long-term support to assist in psychosexual adjustment and decision-making. These adjustments and decisions change as the child matures. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Psychosexual issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of malignant potential in abdominally positioned gonads bearing Y chromosomal material, surgical removal or repositioning into the scrotum is recommended. However, the malignant potential and optimal age for surgery varies substantially among DSDs. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Gonads'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ongoing medical concerns in children with DSDs include the potential for malignancy in gonadal tissue or kidneys, the effects of altered levels of sex steroid exposure, and decreased bone mineral density. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Medical concerns'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/1\">",
"      Lee PA, Houk CP, Ahmed SF, et al. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006; 118:e488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/2\">",
"      Reiner WG. Assignment of sex in neonates with ambiguous genitalia. Curr Opin Pediatr 1999; 11:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/3\">",
"      Daaboul J, Frader J. Ethics and the management of the patient with intersex: a middle way. J Pediatr Endocrinol Metab 2001; 14:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/4\">",
"      Meyer-Bahlburg HF. Gender and sexuality in classic congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/5\">",
"      K&ouml;hler B, Kleinemeier E, Lux A, et al. Satisfaction with genital surgery and sexual life of adults with XY disorders of sex development: results from the German clinical evaluation study. J Clin Endocrinol Metab 2012; 97:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/6\">",
"      Callens N, van der Zwan YG, Drop SL, et al. Do surgical interventions influence psychosexual and cosmetic outcomes in women with disorders of sex development? ISRN Endocrinol 2012; 2012:276742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/7\">",
"      Fagerholm R, Mattila AK, Roine RP, et al. Mental health and quality of life after feminizing genitoplasty. J Pediatr Surg 2012; 47:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/8\">",
"      Callens N, De Cuypere G, Wolffenbuttel KP, et al. Long-term psychosexual and anatomical outcome after vaginal dilation or vaginoplasty: a comparative study. J Sex Med 2012; 9:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/9\">",
"      Speiser PW. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Endocrinol Metab Clin North Am 2001; 30:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/10\">",
"      Diamond M, Sigmundson HK. Management of intersexuality. Guidelines for dealing with persons with ambiguous genitalia. Arch Pediatr Adolesc Med 1997; 151:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/11\">",
"      Douglas G, Axelrad ME, Brandt ML, et al. Consensus in Guidelines for Evaluation of DSD by the Texas Children's Hospital Multidisciplinary Gender Medicine Team. Int J Pediatr Endocrinol 2010; 2010:919707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/12\">",
"      Pasterski V, Prentice P, Hughes IA. Impact of the consensus statement and the new DSD classification system. Best Pract Res Clin Endocrinol Metab 2010; 24:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/13\">",
"      Moran ME, Karkazis K. Developing a multidisciplinary team for disorders of sex development: planning, implementation, and operation tools for care providers. Adv Urol 2012; 2012:604135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/14\">",
"      Palmer BW, Wisniewski AB, Schaeffer TL, et al. A model of delivering multi-disciplinary care to people with 46 XY DSD. J Pediatr Urol 2012; 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/15\">",
"      J&uuml;rgensen M, Kleinemeier E, Lux A, et al. Psychosexual development in children with disorder of sex development (DSD)--results from the German Clinical Evaluation Study. J Pediatr Endocrinol Metab 2010; 23:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/16\">",
"      Hines M. Prenatal testosterone and gender-related behaviour. Eur J Endocrinol 2006; 155 Suppl 1:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/17\">",
"      Diamond M, Beh HG. Changes in the management of children with intersex conditions. Nat Clin Pract Endocrinol Metab 2008; 4:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/18\">",
"      MONEY J, HAMPSON JG, HAMPSON JL. Hermaphroditism: recommendations concerning assignment of sex, change of sex and psychologic management. Bull Johns Hopkins Hosp 1955; 97:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/19\">",
"      Lee MM, Donahoe PK. The infant with ambiguous genitalia. Curr Ther Endocrinol Metab 1997; 6:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/20\">",
"      Evaluation of the newborn with developmental anomalies of the external genitalia. American Academy of Pediatrics. Committee on Genetics. Pediatrics 2000; 106:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/21\">",
"      Reiner WG, Gearhart JP. Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth. N Engl J Med 2004; 350:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/22\">",
"      Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF, et al. Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab 2000; 85:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/23\">",
"      Berenbaum SA, Bailey JM. Effects on gender identity of prenatal androgens and genital appearance: evidence from girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/24\">",
"      Creighton SM, Minto CL, Steele SJ. Objective cosmetic and anatomical outcomes at adolescence of feminising surgery for ambiguous genitalia done in childhood. Lancet 2001; 358:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/25\">",
"      Minto CL, Liao LM, Woodhouse CR, et al. The effect of clitoral surgery on sexual outcome in individuals who have intersex conditions with ambiguous genitalia: a cross-sectional study. Lancet 2003; 361:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/26\">",
"      Schnitzer JJ, Donahoe PK. Surgical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/27\">",
"      Nihoul-F&eacute;k&eacute;t&eacute; C, Thibaud E, Lortat-Jacob S, Josso N. Long-term surgical results and patient satisfaction with male pseudohermaphroditism or true hermaphroditism: a cohort of 63 patients. J Urol 2006; 175:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/28\">",
"      Jordan G, Gilbert D. Phallic construction 2002: Current concepts and future directions. Growth, Genetics &amp; Hormones 2002; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/29\">",
"      Migeon CJ, Wisniewski AB, Gearhart JP, et al. Ambiguous genitalia with perineoscrotal hypospadias in 46,XY individuals: long-term medical, surgical, and psychosexual outcome. Pediatrics 2002; 110:e31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/30\">",
"      Migeon CJ, Wisniewski AB, Brown TR, et al. 46,XY intersex individuals: phenotypic and etiologic classification, knowledge of condition, and satisfaction with knowledge in adulthood. Pediatrics 2002; 110:e32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/31\">",
"      Blanc T, Ayedi A, El-Ghoneimi A, et al. Testicular function and physical outcome in young adult males diagnosed with idiopathic 46 XY disorders of sex development during childhood. Eur J Endocrinol 2011; 165:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/32\">",
"      Reiner WG, Gearhart JP, Jeffs R. Psychosexual dysfunction in males with genital anomalies: late adolescence, Tanner stages IV to VI. J Am Acad Child Adolesc Psychiatry 1999; 38:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/33\">",
"      Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 2005; 34:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/34\">",
"      Slijper FM, Drop SL, Molenaar JC, de Muinck Keizer-Schrama SM. Long-term psychological evaluation of intersex children. Arch Sex Behav 1998; 27:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/35\">",
"      Houk CP, Hughes IA, Ahmed SF, et al. Summary of consensus statement on intersex disorders and their management. International Intersex Consensus Conference. Pediatrics 2006; 118:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/36\">",
"      Karkazis K, Tamar-Mattis A, Kon AA. Genital surgery for disorders of sex development: implementing a shared decision-making approach. J Pediatr Endocrinol Metab 2010; 23:789.",
"     </a>",
"    </li>",
"    <li>",
"     Achenbach TM, Edelbrock C. Manual for the Child Behavior Checklist and Revised Child Behavior Profile, University of Vermont Department of Psychiatry, Burlington, VT 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/38\">",
"      Meyer-Bahlburg HF, Dolezal C, Baker SW, New MI. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008; 37:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/39\">",
"      Meyer-Bahlburg HF, Dolezal C, Baker SW, et al. Gender development in women with congenital adrenal hyperplasia as a function of disorder severity. Arch Sex Behav 2006; 35:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/40\">",
"      Dessens AB, Slijper FM, Drop SL. Gender dysphoria and gender change in chromosomal females with congenital adrenal hyperplasia. Arch Sex Behav 2005; 34:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/41\">",
"      Warne GL. Long-term outcome of disorders of sex development. Sex Dev 2008; 2:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/42\">",
"      Liao LM, Tacconelli E, Wood D, et al. Adolescent girls with disorders of sex development: A needs analysis of transitional care. J Pediatr Urol 2010; 6:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/43\">",
"      Meyer-Bahlburg HF. Gender monitoring and gender reassignment of children and adolescents with a somatic disorder of sex development. Child Adolesc Psychiatr Clin N Am 2011; 20:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/44\">",
"      Looijenga LH, Hersmus R, Oosterhuis JW, et al. Tumor risk in disorders of sex development (DSD). Best Pract Res Clin Endocrinol Metab 2007; 21:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/45\">",
"      Hersmus R, de Leeuw BH, Wolffenbuttel KP, et al. New insights into type II germ cell tumor pathogenesis based on studies of patients with various forms of disorders of sex development (DSD). Mol Cell Endocrinol 2008; 291:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/46\">",
"      Gourlay WA, Johnson HW, Pantzar JT, et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994; 43:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/47\">",
"      Verp MS, Simpson JL. Abnormal sexual differentiation and neoplasia. Cancer Genet Cytogenet 1987; 25:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/48\">",
"      Manuel M, Katayama PK, Jones HW Jr. The age of occurrence of gonadal tumors in intersex patients with a Y chromosome. Am J Obstet Gynecol 1976; 124:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35577/abstract/49\">",
"      Ahmed SF, Hughes IA. The genetics of male undermasculinization. Clin Endocrinol (Oxf) 2002; 56:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5807 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-D91D1357DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35577=[""].join("\n");
var outline_f34_47_35577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL STABILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fluid and electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Family coping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENDER DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Traditional approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Follow-up studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Functional and cosmetic outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Psychosocial outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Current approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Consensus statement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Alternative guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Gender assignment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Genital surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Psychosexual issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medical concerns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gonads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19037640\">",
"      Gonadectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19037647\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Sex steroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUPPORT GROUPS AND INTERNET SITES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Gender assignment and surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Long-term issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5807|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/15/17649\" title=\"figure 1A\">",
"      Virilization cross section view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/60/29634\" title=\"figure 1B\">",
"      Virilization external view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5807|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/0/39949\" title=\"table 1\">",
"      Different forms of CAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/54/23405\" title=\"table 2\">",
"      Rapid overview adrenal crisis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/57/41884\" title=\"table 3\">",
"      Projected gender identity for DSDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30423?source=related_link\">",
"      Steroid 5-alpha-reductase 2 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11849?source=related_link\">",
"      Surgical management and postoperative outcome of children with bladder exstrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/0/31754?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_47_35578="Approach to the patient with hypertriglyceridemia";
var content_f34_47_35578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with hypertriglyceridemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35578/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35578/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35578/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35578/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/47/35578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/47/35578/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/47/35578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid disorders can occur as either a primary event or secondary to some underlying disease (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=see_link\">",
"     \"Secondary causes of dyslipidemia\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/1\">",
"     1",
"    </a>",
"    ]. The primary dyslipidemias are associated with overproduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired removal of lipoproteins (",
"    <a class=\"graphic graphic_table graphicRef54329 \" href=\"mobipreview.htm?20/51/21307\">",
"     table 1",
"    </a>",
"    ). The latter defect can be induced by an abnormality in either the lipoprotein itself or in the lipoprotein receptor. Lipoprotein lipase (LPL) hydrolyzes triglycerides contained in the core of chylomicrons and very low density lipoprotein (VLDL); it also facilitates cholesterol transfer from these lipoproteins to high density lipoprotein (HDL) (",
"    <a class=\"graphic graphic_figure graphicRef51771 \" href=\"mobipreview.htm?8/29/8657\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51253 \" href=\"mobipreview.htm?5/4/5199\">",
"     figure 2",
"    </a>",
"    ). The hydrolysis of triglycerides releases free fatty acids that are then used as an energy source, converted to triglyceride, or stored in adipose tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H11#H11\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Endogenous pathway of lipid metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One definition of dyslipidemia is total cholesterol, low density lipoprotein-cholesterol (LDL-C), triglyceride, apolipoprotein (apo)-B, or Lp(a) levels above the 90th percentile or high density lipoprotein-cholesterol (HDL-C) or apo A-I levels below the 10th percentile for the general population (",
"    <a class=\"graphic graphic_table graphicRef71803 \" href=\"mobipreview.htm?18/63/19453\">",
"     table 2",
"    </a>",
"    ). Lipoprotein metabolism and the function of the different apolipoproteins is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the evidence that hypertriglyceridemia contributes to the development of atherosclerosis, the mechanisms by which this might occur, the disorders of triglyceride metabolism that have been identified, and recommendations for the management of hypertriglyceridemia. The pathways involved in normal triglyceride synthesis and metabolism are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H11#H11\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Endogenous pathway of lipid metabolism'",
"    </a>",
"    ). The management of patients with hypertriglyceridemia who have acute or prior pancreatitis is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31064?source=see_link\">",
"     \"Hypertriglyceridemia-induced acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders of LDL and HDL metabolism and the management of lipids for primary and secondary prevention are also discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"       \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS, EPIDEMIOLOGY, AND DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum triglyceride concentration can be stratified in terms of population percentiles",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary risk (",
"    <a class=\"graphic graphic_table graphicRef71803 \" href=\"mobipreview.htm?18/63/19453\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal &mdash; &lt;150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Borderline high &mdash; 150 to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7 to 2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      High &mdash; 200 to 499",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.3 to 5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Very high &mdash; &ge;500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;5.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To convert from",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    divide by 88.5.",
"   </p>",
"   <p>",
"    In this topic, when discussing management, we refer to the range of fasting triglyceride levels from 150 to 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7 to 5.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    as &ldquo;mild to moderate&rdquo; hypertriglyceridemia and levels above 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    as &ldquo;severe&rdquo; hypertriglyceridemia.",
"   </p>",
"   <p>",
"    Hyperlipidemia is common, but varies with the population being studied. In the United States, the National Health and Nutrition Examination Surveys (NHANES) from 1999 to 2004 found that the percentage of adults with triglyceride levels above 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was 33, 18, 1.7, and 0.4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of hyperlipidemia is highest in patients with premature coronary disease (CHD), which can be defined as occurring before 55 years of age in men and before 65 years in women. In such patients, the prevalence of dyslipidemia is as high as 80 to 88 percent, compared to approximately 40 to 48 percent in age-matched controls without coronary heart disease (CHD) (",
"    <a class=\"graphic graphic_figure graphicRef59944 \" href=\"mobipreview.htm?15/40/16014\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertriglyceridemia is commonly detected when a lipid profile is obtained to screen for cardiovascular risk. Disturbances in lipoprotein metabolism are often familial. In one study of 102 kindred in which the proband had premature coronary disease, 54 percent of all patients (and 70 percent of those with a lipid abnormality) had a familial lipid disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/4\">",
"     4",
"    </a>",
"    ]. The most common were lipoprotein(a) excess (alone or with other dyslipidemia), hypertriglyceridemia with hypoalphalipoproteinemia, and combined hyperlipidemia. Because of the association among dyslipidemia, premature CHD, and a family history of CHD, a screening lipid analysis is recommended for first-degree relatives of patients with premature CHD, as well as for many other adult men and women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRIGLYCERIDES AND ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the contribution of triglycerides to cardiovascular risk has been debated in the past, it now seems clear that elevated triglyceride levels are independently associated with cardiovascular risk, particularly coronary risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/6\">",
"     6",
"    </a>",
"    ]. It remains uncertain, however, whether this association is causal, such that hypertriglyceridemia causes atherosclerosis. While cholesterol accumulates in atherosclerotic arteries in large quantities, triglyceride only accumulates to a minor extent. It is also uncertain whether lowering triglyceride levels reduces cardiovascular risk.",
"   </p>",
"   <p>",
"    The effect of abnormal triglyceride metabolism on atherosclerosis has been studied by evaluating the incidence of coronary events, the contribution of triglyceride-containing lipoproteins to atherosclerosis progression, and the incidence of cerebrovascular ischemic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A Mendelian randomization study suggested that triglyceride-mediated pathways are causally involved in coronary heart disease, though could not directly assess whether triglycerides themselves cause coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H470902041\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between hypertriglyceridemia and coronary heart disease (CHD) has been studied both in angiographic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/11-17\">",
"     11-17",
"    </a>",
"    ], and in studies evaluating CHD events. Studies evaluating CHD events include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2007 report of two large prospective studies involving over 3500 CHD cases and 44,000 middle-aged women and men, plus a meta-analysis of 27 prospective population-based studies involving a total of over 10,000 incident CHD cases and 260,000 participants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/18\">",
"       18",
"      </a>",
"      ]. The combined adjusted odds ratio for CHD comparing individuals in the top third of serum triglyceride levels with those in the bottom third was 1.7 (95% CI 1.6-1.9). Although hypertriglyceridemia had been thought to be more predictive of CHD risk in women, the relative risks appeared similar in men and women in the meta-analysis.",
"     </li>",
"     <li>",
"      A 2007 study of nearly 14,000 untreated younger males, aged 26 to 45 years, who had serum triglycerides measured five years apart calculated a substantially higher risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/19\">",
"       19",
"      </a>",
"      ]. After a mean follow up of 10.5 years, the study findings were as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Triglycerides at first measurement were strongly and independently associated with CHD risk when comparing those in the highest quintile to those in the lowest (multivariate hazard ratio 4.1).",
"     </li>",
"     <li>",
"      Increase in the triglyceride levels between the initial and the second measurement was associated with an additional increase in CHD risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The difference in the CHD risk between the two studies cited above may be explained by the fact that the mean age of the two cohorts was different; the older population had a lower relative risk. As the population ages and the CHD risk goes up on an absolute scale, the relative risk of individual factors may go down.",
"   </p>",
"   <p>",
"    Hypertriglyceridemia is also associated with increased mortality in patients with known CHD, and both increased mortality and reduced event-free survival after coronary artery bypass graft surgery (CABG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, although triglyceride levels are commonly measured fasting (and normal ranges are standardized for these fasting levels), two studies found that nonfasting triglyceride levels were associated with cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H470902414\">",
"    <span class=\"h2\">",
"     Cerebrovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although much of the evidence linking cardiovascular disease and triglyceride levels involves CHD, patients with increased triglyceride levels are likely also at risk for other vascular events. Two large studies found that increased nonfasting triglyceride levels are associated with an increased risk for ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Importance of associated abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a possible direct role, hypertriglyceridemia tends to be associated with other abnormalities that themselves predispose to atherosclerosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low levels of HDL-C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of small, dense LDL particles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/16,28\">",
"       16,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of atherogenic triglyceride-rich lipoprotein remnants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link&amp;anchor=H17#H17\">",
"       \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Intermediate density lipoprotein (remnant lipoproteins)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Insulin resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link&amp;anchor=H5#H5\">",
"       \"Insulin resistance: Definition and clinical spectrum\", section on 'Biochemical markers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increases in coagulability and viscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]; triglyceride-mediated hyperviscosity may contribute to endothelial dysfunction, tissue ischemia, and the chylomicronemia syndrome (see below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low levels of HDL-C appear to interact with hypertriglyceridemia to increase coronary risk (",
"    <a class=\"graphic graphic_figure graphicRef67263 \" href=\"mobipreview.htm?6/9/6302\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The mechanism responsible for low HDL-C concentrations results from increased catabolism of triglyceride-enriched HDL particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/39\">",
"     39",
"    </a>",
"    ]. In individuals with hypertriglyceridemia, and normolipidemic individuals with abnormal postprandial triglyceride responses, cholesteryl ester transfer protein (CETP) mediates transfer of core triglyceride in VLDL with core cholesterol in HDL (and LDL) that results in triglyceride-enriched HDL (and LDL) particles. The triglyceride-enriched HDL (and LDL) particles are substrates for hepatic lipase, which hydrolyzes the core triglyceride in HDL (and LDL) resulting in the formation of a lipid-depleted and smaller size HDL (and LDL) particle. Smaller HDL particles contain less apolipoprotein A-I (apo A-I) proteins per HDL particle. The shedding of apo A-I from the HDL particle results in filtration through the glomerulus and degradation by renal tubular cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/39\">",
"     39",
"    </a>",
"    ]. In normolipidemic men, an infusion of triglycerides increases the triglyceride content of HDL-C twofold, enhancing the clearance of HDL apo A-I from the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/40\">",
"     40",
"    </a>",
"    ]. Another possible contributing factor is high levels of cholesterol ester transfer protein, which diverts cholesterol esters from HDL to triglyceride-rich lipoproteins in exchange for triglycerides (",
"    <a class=\"graphic graphic_figure graphicRef51253 \" href=\"mobipreview.htm?5/4/5199\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/41\">",
"     41",
"    </a>",
"    ]. Why this might occur is not known.",
"   </p>",
"   <p>",
"    Small dense LDL particles appear to be particularly atherogenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Both the Physician's Health Study and the SCRIP trial found an inverse correlation between serum triglycerides and LDL diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/16,42\">",
"     16,42",
"    </a>",
"    ]. In the SCRIP trial, for example, a fasting triglyceride level above 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.81",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was associated with an LDL-dense-mode in 90 percent of subjects; in comparison, a triglyceride concentration below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.13",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was associated with an LDL buoyant-mode in 90 percent of subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H22#H22\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Small dense LDL (LDL phenotype B)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DISORDERS OF TRIGLYCERIDE METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolic regulation of fasting and postprandial triglyceride and HDL concentrations is modulated by lipoprotein ligands and the combined actions of LPL, hepatic lipase, and cholesteryl ester transfer protein (CETP) (",
"    <a class=\"graphic graphic_figure graphicRef51771 \" href=\"mobipreview.htm?8/29/8657\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51253 \" href=\"mobipreview.htm?5/4/5199\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/41,44,45\">",
"     41,44,45",
"    </a>",
"    ]. Both inherited and acquired disorders of triglyceride metabolism have been identified (",
"    <a class=\"graphic graphic_table graphicRef75442 \" href=\"mobipreview.htm?38/34/39467\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum triglyceride values above 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    occur in fewer than 1 in 5000 individuals. The serum in these patients is opalescent due to an increase in VLDL; at higher levels, it may be milky due to hyperchylomicronemia. Most of these patients have one of the dyslipidemias described below with an additional condition known to raise serum triglycerides (eg, diabetes mellitus, alcohol abuse, or estrogen or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An emergent problem that may be associated with marked hypertriglyceridemia is acute pancreatitis. In one series of 70 such patients, the mean serum triglyceride concentration was 4587 (52",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/50\">",
"     50",
"    </a>",
"    ]. Affected patients typically present with the acute onset of abdominal pain, nausea, and vomiting, and the serologic features of pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The above report found three characteristic profiles in patients presenting with hypertriglyceridemia-induced pancreatitis (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology of acute pancreatitis\", section on 'Hypertriglyceridemia'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A poorly controlled diabetic with a history of hypertriglyceridemia. This was the most common presentation. Part of the therapy of such patients is the administration of insulin which will rapidly lower the serum triglyceride concentration.",
"     </li>",
"     <li>",
"      An abuser of alcohol found to have hypertriglyceridemia or lactescent serum on hospital admission.",
"     </li>",
"     <li>",
"      A nondiabetic, nonalcoholic, nonobese patient with drug- or diet-induced hypertriglyceridemia; these patients accounted for 15 to 20 percent of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acquired disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of acquired disorders, conditions, and therapies raise serum triglycerides, a change that may be particularly important in patients with underlying defects in triglyceride metabolism. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity, often in association with an elevation in serum cholesterol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"       \"Health hazards associated with obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetes mellitus, where there is a relationship to poor glycemic control and, in type 2 diabetes, obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/47,52\">",
"       47,52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrotic syndrome, often in association with hypercholesterolemia, and renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothyroidism, often in association with hypercholesterolemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28550?source=see_link\">",
"       \"Lipid abnormalities in thyroid disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13274?source=see_link&amp;anchor=H15#H15\">",
"       \"Maternal endocrine and metabolic adaptation to pregnancy\", section on 'Lipid metabolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estrogen replacement, which is often associated with a fall in LDL-C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/48,56\">",
"       48,56",
"      </a>",
"      ]. The elevation in serum triglycerides may not be seen with transdermal estrogen delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/57\">",
"       57",
"      </a>",
"      ]. Oral contraceptives may also increase serum triglyceride concentrations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      can cause marked hypertriglyceridemia in a minority of women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=see_link&amp;anchor=H9#H9\">",
"       \"Managing the side effects of tamoxifen\", section on 'Coronary heart disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta blockers; on the other hand, alpha blockers lower serum triglycerides, while low dose diuretics, angiotensin converting enzyme inhibitors, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      have little or no effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44659?source=see_link\">",
"       \"Antihypertensive drugs and lipids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunosuppressive medications, such as glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. The effect of glucocorticoids is associated with insulin resistance and appears to be mediated in part by suppression of ACTH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HIV antiretroviral regimens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=see_link&amp;anchor=H27#H27\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\", section on 'Lipid abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retinoids. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=see_link&amp;anchor=H10#H10\">",
"       \"Oral isotretinoin therapy for acne vulgaris\", section on 'Other side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chylomicronemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting chylomicronemia (type V hyperlipoproteinemia; Mixed hypertriglyceridemia) is characterized by triglyceride levels above the 99th percentile in association with a creamy plasma supernatant and cloudy infranatant due to increases in chylomicrons and VLDL (",
"    <a class=\"graphic graphic_picture graphicRef76826 \" href=\"mobipreview.htm?11/50/12066\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The clinical manifestations include hepatosplenomegaly and occasional eruptive xanthomas. However, patients with marked hypertriglyceridemia (&gt;1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    may develop the chylomicronemia syndrome. Manifestations of this disorder include recent memory loss, abdominal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pancreatitis, dyspnea, eruptive xanthoma (",
"    <a class=\"graphic graphic_picture graphicRef82268 \" href=\"mobipreview.htm?31/38/32353\">",
"     picture 2",
"    </a>",
"    ), flushing with alcohol, and lipemia retinalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Familial dysbetalipoproteinemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most patients have a secondary form in which some other dyslipidemia (eg, familial hypertriglyceridemia due to partial LPL deficiency) is exacerbated by one or more of the acquired disorders noted above. There is also a primary form of type V hyperlipoproteinemia in which there is no deficiency in LPL or its ligand apo C-II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The underlying defect in this disorder is uncertain but apo E4, which is a ligand for the hepatic chylomicron and VLDL remnant receptor, may play a role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fasting chylomicronemia can be diagnosed by confirming the presence of chylomicrons and excess VLDL on agarose gel electrophoresis or ultracentrifugal analysis. A simple technique is to refrigerate plasma overnight and examine the specimen for a creamy supernatant from chylomicrons and a turbid VLDL-rich infranatant.",
"   </p>",
"   <p>",
"    This latter finding of a turbid infranatant is not seen in patients with type I hyperlipoproteinemia, in which only chylomicrons accumulate and the infranatant is clear. Patients with type I hyperlipoproteinemia generally have complete absence of either lipoprotein lipase (LPL) activity (type Ia) or apo C-II, the ligand for lipoprotein lipase on chylomicrons and VLDL (type Ib) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. This is in contrast to the partial deficiency when the type V phenotype is associated with exacerbation of familial hypertriglyceridemia by the administration of estrogen or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type Ia hyperlipoproteinemia is an extremely rare genetic disorder that results from homozygous deficiency in lipoprotein lipase activity. It is characterized by eruptive xanthomas, lipemia retinalis, and frequent episodes of pancreatitis. The only effective therapy has been a strict low-fat diet. A gene therapy for this condition, LPL(S447X) gene variant, in an adeno-associated viral vector of serotype 1 (alipogene tiparvovec [Glybera]), has been approved for use in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/67\">",
"     67",
"    </a>",
"    ], making it the first gene therapy approved for use in people.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Familial hypertriglyceridemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial hypertriglyceridemia (type IV hyperlipoproteinemia phenotype) is an autosomal dominant disorder associated with moderate elevations in the serum triglyceride concentration (200 to 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.3 to 5.6",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    It is often accompanied by insulin resistance, obesity, hyperglycemia, hypertension, and hyperuricemia.",
"   </p>",
"   <p>",
"    Patients with familial hypertriglyceridemia are heterozygous for inactivating mutations of the LPL gene and, as noted above, typically have low serum HDL-C (hypoalphalipoproteinemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/25,66\">",
"     25,66",
"    </a>",
"    ]. The common LPL mutations raise serum triglycerides by 20 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/25\">",
"     25",
"    </a>",
"    ]. More marked elevations require some other factor such as one of the drugs or acquired disorders noted above, such as estrogen replacement therapy in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Acquired disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Familial hypertriglyceridemia is associated with increased coronary risk and is common in patients with premature CHD. One report, for example, evaluated patients undergoing coronary arteriography prior to age 55 years; the prevalence of familial hypertriglyceridemia with hypoalphalipoproteinemia was 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/4\">",
"     4",
"    </a>",
"    ]. Among first-degree relatives of affected patients, baseline serum triglycerides predict cardiovascular mortality, independent of serum total cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Familial combined hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial combined hyperlipidemia (FCHL) is a disorder caused by overproduction of hepatically-derived apolipoprotein B-100 associated with VLDL. It is associated with a clear increase in coronary risk and accounts for one-third to one-half of familial causes of CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H16#H16\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial combined hyperlipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary defect in FCHL is not known but a locus has been identified on chromosome 1q21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/69\">",
"     69",
"    </a>",
"    ]. Affected patients typically present with hypercholesterolemia and hypertriglyceridemia, but either abnormality alone also may be seen. LPL may be responsible for part of this phenotypic variability as hypertriglyceridemia is more prominent in patients with LPL deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/70\">",
"     70",
"    </a>",
"    ]. In at least some patients, a mutation in the LPL gene is responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Familial dysbetalipoproteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial dysbetalipoproteinemia (type III hyperlipoproteinemia) is a multifactorial disorder that is inherited as an autosomal recessive trait. It is characterized by the presence of two apo E2 alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Premature CHD and peripheral vascular disease are common. Physical findings include tuberoeruptive xanthomas (",
"    <a class=\"graphic graphic_picture graphicRef78663 \" href=\"mobipreview.htm?36/55/37746\">",
"     picture 3",
"    </a>",
"    ) and xanthomas of the palmar creases (xanthomata palmare striatum) (",
"    <a class=\"graphic graphic_picture graphicRef58173 \" href=\"mobipreview.htm?11/32/11776\">",
"     picture 4",
"    </a>",
"    ). An additional genetic or acquired factor that increases lipoprotein production or impairs lipoprotein removal is typically required for full clinical expression; examples include diabetes mellitus, hypothyroidism, obesity, or gout (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Acquired disorders'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/72\">",
"     72",
"    </a>",
"    ]; a similar effect is seen in an animal model of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apo E ligand is required for receptor-mediated clearance of chylomicron and VLDL remnants from the circulation. The most common apo E isoform is E",
"    <span class=\"nowrap\">",
"     3/3.",
"    </span>",
"    The apo E2 ligand has a lower affinity for the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor than apo E3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/75\">",
"     75",
"    </a>",
"    ]. Thus, VLDL remnants that contain apo E2 on their surface are not cleared as efficiently from the plasma. This results in the formation of a dense VLDL particle known as beta-VLDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/73\">",
"     73",
"    </a>",
"    ]. Chylomicron remnants also possess apo E2 and accumulate in this disorder.",
"   </p>",
"   <p>",
"    Laboratory findings are characterized by increased concentrations of triglyceride and cholesterol (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Hypertriglyceridemia and serum cholesterol'",
"    </a>",
"    below). Beta-VLDL can be detected on agarose gel electrophoresis. The VLDL-cholesterol to triglyceride ratio is greater than 0.3 (the normal ratio is 0.2). Apo E isoform analysis is performed by isoelectric focusing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypertriglyceridemia and serum cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertriglyceridemia reflects the accumulation of triglyceride-rich lipoproteins (chylomicrons, VLDL and remnant particles, beta-VLDL, and IDL) in plasma. Since triglyceride-rich lipoproteins also transport cholesterol, hypercholesterolemia of varying severity often accompanies hypertriglyceridemia. The magnitude of the hypercholesterolemia depends upon the number and composition of triglyceride-rich lipoproteins that are present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chylomicrons and large VLDL particles transport relatively little cholesterol and therefore produce mild to modest increases in serum cholesterol when they are responsible for hypertriglyceridemia.",
"     </li>",
"     <li>",
"      The elevation in serum cholesterol is more pronounced when hypertriglyceridemia is due to accumulation of small VLDL, beta-VLDL, or IDL particles, which are enriched with cholesterol. As an example, the serum cholesterol and triglyceride concentrations are often comparably elevated (in terms of absolute values) in patients with dysbetalipoproteinemia (type III) because beta-VLDL is enriched equally with cholesterol and triglyceride compared to ordinary VLDL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient with concurrent hypertriglyceridemia and hypercholesterolemia has a variable risk of atherosclerosis when compared with similar degrees of hypercholesterolemia due to disorders of LDL metabolism (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    ). In particular, the accumulation of chylomicrons or large VLDL particles is associated with a lesser risk of atherosclerosis because of an inability of these particles to deposit in the vessel wall; they can, however, cause pancreatitis.",
"   </p>",
"   <p>",
"    In contrast, small VLDL, IDL, and beta-VLDL are more inherently atherogenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/13,76-79\">",
"     13,76-79",
"    </a>",
"    ]. Large VLDL particles serve as a substrate for CETP that allows for more lipid exchange between VLDL, LDL, and HDL. The triglyceride enriched LDL and HDL are hydrolyzed by hepatic lipase to smaller LDL and HDL subclasses, respectively. Often, these patients have high LDL particle concentrations (and apolipoprotein B) without an associated increase in LDL-C, and low HDL particle concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the presence of hypertriglyceridemia should suggest that any increase in serum total cholesterol is due, at least in part, to increased VLDL-cholesterol. This relationship also has therapeutic implications since therapy aimed at reducing triglyceride-rich lipoproteins and serum triglyceride concentrations with fibrates or nicotinic acid will be associated with reductions in serum total cholesterol; in comparison, statins have a smaller effect on VLDL (especially large VLDL particles) than on LDL and therefore have less cholesterol-lowering effects in such patients. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723637349\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data regarding which patients with hypertriglyceridemia require treatment and on the choice of therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H723637365\">",
"    <span class=\"h2\">",
"     Mild to moderate hypertriglyceridemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mild to moderate hypertriglyceridemia (150 to 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.7 to 5.7",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    and even in patients with triglyceride levels as high as 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the main indication for therapy is reduction of cardiovascular (CV) risk. Lifestyle changes are a central part of managing such patients (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Nonpharmacologic therapy'",
"    </a>",
"    below). Pharmacologic therapy for CV risk reduction, over a wide range of lipid profiles and baseline risks, has been best proven with statin therapy (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Statins'",
"    </a>",
"    ). Even though statins are not the most effective medications in reducing serum triglyceride levels, they are the most effective hypolipidemic agents in reducing CV risk and, as such, should probably be first line therapy in patients with mild to moderate hypertriglyceridemia where the goal of therapy is CV risk reduction.",
"   </p>",
"   <p>",
"    While no trials of statins have looked specifically at patients with normal LDL-C and elevated triglycerides, the mean baseline LDL-C in the Heart Protection Study (HPS) was 131",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/81\">",
"     81",
"    </a>",
"    ]. In HPS, patients with baseline triglyceride levels above 354",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who were randomized to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    therapy rather than placebo had a similar reduction in cardiovascular events to patients with lower triglyceride levels who received simvastatin.",
"   </p>",
"   <p>",
"    It is uncertain whether pharmacologic therapy targeted at reducing triglyceride levels will reduce CV risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/7\">",
"     7",
"    </a>",
"    ]. As discussed above, however, epidemiologic data do provide strong evidence of a link between triglyceride levels and CV risk (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Triglycerides and atherosclerosis'",
"    </a>",
"    above). Additionally, several randomized trials performed in patients with coronary heart disease or coronary risk equivalents raise the possibility that pharmacologic treatment targeting triglycerides, either alone or in combination with statins, could provide clinical benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Helsinki Heart Study, CHD risk was highest in the cohort with a triglyceride level &gt;201",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and an",
"      <span class=\"nowrap\">",
"       LDL-C/HDL-C",
"      </span>",
"      ratio &gt;5.0 (",
"      <a class=\"graphic graphic_figure graphicRef67263 \" href=\"mobipreview.htm?6/9/6302\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/38\">",
"       38",
"      </a>",
"      ]. A benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      therapy was confined to this high-risk subgroup.",
"     </li>",
"     <li>",
"      The VA-HIT trial assessed the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      therapy in patients with low HDL-C (&le;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.0",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      relatively low LDL-C (&le;140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 3.6",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and triglyceride levels &le;300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/82\">",
"       82",
"      </a>",
"      ]. Gemfibrozil raised HDL-C by 6 percent, lowered triglycerides by 31 percent, and had no significant effect on LDL-C. At five years, there was an absolute risk reduction of 4.4 percent, more than could be explained by the increase in HDL-C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the ACCORD Lipid trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      showed no overall benefit when added to a statin in patients with type 2 diabetes, but did improve outcomes in the subset of patients with both elevated triglyceride levels (&gt;204",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.30",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and low HDL-C levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/83\">",
"       83",
"      </a>",
"      ]. This subset analysis was pre-planned because of similar suggestions of benefit with fenofibrate in such subgroups that had previously been seen in the Helsinki Heart Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/38\">",
"       38",
"      </a>",
"      ], the FIELD trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/84\">",
"       84",
"      </a>",
"      ], and The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12933?source=see_link\">",
"       Bezafibrate",
"      </a>",
"      Infarction Prevention (BIP) trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, when the goal is CV risk reduction, decisions about initiating pharmacologic therapy should be based on global cardiovascular risk and individualized based on patient values and preferences, informed by expected risk reductions and side effects with pharmacologic interventions. Nearly all patients with known coronary heart disease (CHD) or a CHD risk equivalent (",
"    <a class=\"graphic graphic_table graphicRef71255 \" href=\"mobipreview.htm?43/30/44523\">",
"     table 4",
"    </a>",
"    ) will require therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Deciding whom to treat'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Identification of patients at risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, when the decision is made to treat, we prefer statin therapy to therapy directed at lowering triglyceride levels in patients with mild to moderate hypertriglyceridemia. In patients with very high triglyceride levels (&gt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.7",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    the triglyceride is carried in chylomicrons",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    very large VLDL particles and we feel that other therapies such as fibrates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fish oil are preferable. Given the more extensive data from randomized trials on microvascular benefits (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link&amp;anchor=H3#H3\">",
"     \"Lipid lowering with fibric acid derivatives\", section on 'Mechanism/Efficacy'",
"    </a>",
"    ), we typically start with a fibrate rather than fish oil. After the triglyceride levels have been lowered from very high levels, a statin may be added to fenofibrate or fish oil.",
"   </p>",
"   <p>",
"    While higher risk patients with CHD or a CHD risk equivalent (",
"    <a class=\"graphic graphic_table graphicRef71255 \" href=\"mobipreview.htm?43/30/44523\">",
"     table 4",
"    </a>",
"    ) and very high triglycerides should be treated with a statin plus a fibrate or fish oil whenever possible, the evidence is less clear in lower risk patients with very high triglycerides who require CV risk reduction. Although we prefer combination therapy, an alternative strategy would be to treat such patients with a statin alone.",
"   </p>",
"   <p>",
"    Also as discussed above, we would generally initiate statin therapy in patients with CHD or a CHD risk equivalent (",
"    <a class=\"graphic graphic_table graphicRef71255 \" href=\"mobipreview.htm?43/30/44523\">",
"     table 4",
"    </a>",
"    ) who have moderate hypertriglyceridemia (200 to 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.3 to 5.7",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    When such patients are intolerant of statin therapy, we suggest treatment with nicotinic acid or a fibrate, given the evidence for CV benefits with these agents. Fish oil is an alternative option. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link&amp;anchor=H5#H5\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Nicotinic acid (Niacin)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link&amp;anchor=H3#H3\">",
"     \"Lipid lowering with fibric acid derivatives\", section on 'Mechanism/Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link&amp;anchor=H13#H13\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Cardiovascular outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic therapy should not be administered for the purpose of reducing the risk of pancreatitis in patients with only mild to moderate elevations in triglyceride level. As discussed below, the risk of pancreatitis is very small and fibrate therapy, in particular, may actually increase this risk in such patients. (See",
"    <a class=\"local\" href=\"#H300298\">",
"     'Severe hypertriglyceridemia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H301366\">",
"     'Fibrates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300298\">",
"    <span class=\"h2\">",
"     Severe hypertriglyceridemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with very elevated triglyceride levels are at increased risk of pancreatitis. The management of patients with hypertriglyceridemia and acute pancreatitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a prior episode of pancreatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31064?source=see_link\">",
"     \"Hypertriglyceridemia-induced acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients without a prior episode of pancreatitis, the risk from hypertriglyceridemia appears to be quite small except with very elevated levels of triglycerides. Despite a recommendation from the United States National Cholesterol Education Program (NCEP) to initiate treatment to prevent pancreatitis when triglyceride levels are above 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H300925\">",
"     'Recommendations of others'",
"    </a>",
"    below), pancreatitis appears to be infrequent unless the triglyceride level is much higher than this cutoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. Although high quality evidence is lacking, for primary prevention of pancreatitis, we and others suggest initiating pharmacologic therapy to reduce triglycerides when the fasting concentration exceeds 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/28,89,90\">",
"     28,89,90",
"    </a>",
"    ]; the triglyceride level in such patients may increase to &gt;2000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    after a high-fat meal. However, even at these levels, the risk of pancreatitis from untreated hypertriglyceridemia is likely quite low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertriglyceridemia is often induced or exacerbated by secondary, potentially correctable disorders (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Acquired disorders'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/11,91\">",
"     11,91",
"    </a>",
"    ]. Thus, nonpharmacologic interventions such as weight loss in obese patients, aerobic exercise, avoidance of concentrated sugars and medications that raise serum triglyceride levels, and strict glycemic control in diabetics should be first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/11,47,91\">",
"     11,47,91",
"    </a>",
"    ]. Other risk factors for cardiovascular disease, such as hypertension and smoking, should also be addressed.",
"   </p>",
"   <p>",
"    The effect of lifestyle modification on serum triglycerides is most apparent in men. One report evaluated the effect of a hypocaloric NCEP diet with or without aerobic exercise in overweight men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/92\">",
"     92",
"    </a>",
"    ]. Most patients met or came close to the diet goals, with a mean reduction in fat weight of 4.0 to 7.8 kg at one year. In men, serum triglycerides fell by 8 percent with diet alone and by 33 percent with diet plus exercise. In women, diet alone produced no change and the addition of exercise caused only a slight fall in serum triglycerides.",
"   </p>",
"   <p>",
"    Appropriate dietary management of hypertriglyceridemia differs between mild-to-moderate and severe hypertriglyceridemia.",
"   </p>",
"   <p>",
"    Plasma triglycerides are composed of two distinct classes of lipoproteins: chylomicrons originating from dietary fat absorbed through intestinal cells, and VLDL created from triglyceride in the liver. In most people, chylomicrons deliver their triglyceride load to peripheral tissues very rapidly and disappear from plasma soon after intestinal fat absorption is completed. As a result, moderate fasting hypertriglyceridemia is due to VLDL. The liver fat used to make VLDL comes mainly from two sources:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma nonesterified fatty acids derived from lipolysis of adipocyte triglyceride. Lipolysis in adipocytes and fatty acid flux to the liver are augmented by obesity, diabetes mellitus, and insulin resistance.",
"     </li>",
"     <li>",
"      De novo synthesis of fatty acids and triglyceride in the liver mainly from carbohydrates. High glycemic and high fructose diets enhance this process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For this reason, dietary management of moderate hypertriglyceridemia should focus on &ldquo;eating less&rdquo; to lose weight, and also on reduction of carbohydrates, especially high glycemic and high fructose foods. Dietary fat is not a primary source for liver triglyceride, and higher fat diets do not raise fasting plasma triglyceride levels in most people. For patients with mild-to-moderate hypertriglyceridemia who are above their ideal body weight, we suggest a hypocaloric diet in combination with regular moderate-to-intense aerobic exercise. The diet should restrict consumption of high glycemic",
"    <span class=\"nowrap\">",
"     index/load",
"    </span>",
"    foods (",
"    <a class=\"graphic graphic_table graphicRef71978 \" href=\"mobipreview.htm?8/40/8845\">",
"     table 5",
"    </a>",
"    ) including refined sugars, fruit juices, and high fructose beverages; we suggest increased consumption of fish that contain high amounts of omega-3 fatty acids (",
"    <a class=\"graphic graphic_table graphicRef79454 \" href=\"mobipreview.htm?40/29/41435\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At fasting triglyceride levels above 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6 to 11.3",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    (the exact threshold is unclear and may vary among individuals), the clearance of chylomicrons from the blood becomes very slow, such that chylomicrons from the previous night&rsquo;s meal are still present in morning fasting blood. This sets the stage for enormous accumulation of chylomicron triglyceride derived from dietary fat, leading to a risk for pancreatitis and other manifestations of fasting chylomicronemia. Therefore, at very high fasting triglyceride levels (especially above 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.3",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    it is crucial to restrict dietary fat greatly, to less than 25 to 40 g daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/90\">",
"     90",
"    </a>",
"    ]. Patients need to be reminded that even &ldquo;good fat&rdquo; such as vegetable oils and nuts, as well as fat contained in chips and pastries, can raise their triglyceride levels and cause pancreatitis.",
"   </p>",
"   <p>",
"    Diets aimed at weight loss should be used cautiously, if at all, in patients with severe hypertriglyceridemia, and weight loss should generally be avoided until other therapies have reduced fasting triglyceride levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/90\">",
"     90",
"    </a>",
"    ]. This is because when the weight-loss diet ends and refeeding begins, such patients are likely to develop very high triglyceride levels with a resultant increased risk of pancreatitis.",
"   </p>",
"   <p>",
"    Alcohol abuse must be avoided in patients with severe hypertriglyceridemia as it can cause large increases in triglyceride levels precipitate pancreatitis. The effects of moderate alcohol consumption in patients with mild-to-moderate hypertriglyceridemia are less clear and may have only a limited effect on triglyceride levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/93\">",
"     93",
"    </a>",
"    ]. This observation may be important in those with other risk factors for CV disease in whom moderate alcohol consumption can improve coronary risk (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    ). Given the potential risks of alcohol consumption in patients with hypertriglyceridemia, and while awaiting further study, we suggest that in patients with mild to moderate hypertriglyceridemia, men limit their alcohol consumption to no more than two drinks per day and women limit their consumption to no more than one drink per day.",
"   </p>",
"   <p>",
"    Since not all patients with severe hypertriglyceridemia have a significant increase in triglyceride levels with alcohol consumption, an alternative strategy is to check for alcohol responsiveness by measuring triglycerides soon after consuming alcohol and after a period of several weeks abstaining from alcohol. Patients whose triglyceride levels do not significantly increase with alcohol consumption may be able to safely consume moderate amounts of alcohol, similar to patients with mild to moderate hypertriglyceridemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy (including fish oil)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents can be used to reduce triglyceride levels (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"mobipreview.htm?21/47/22268\">",
"     table 7",
"    </a>",
"    ). Randomized trials have not directly compared most agents for prevention of CV disease in patients with hypertriglyceridemia. As discussed above, although statin therapy is less effective in reducing triglyceride levels than fibrates, nicotinic acid, or fish oil, the proven ability of statins to reduce CV risk make them the preferred agents when CV risk reduction is the goal of therapy. (See",
"    <a class=\"local\" href=\"#H723637365\">",
"     'Mild to moderate hypertriglyceridemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with severe hypertriglyceridemia (&gt;1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.3",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    one goal of therapy is the prevention of pancreatitis (see",
"    <a class=\"local\" href=\"#H300298\">",
"     'Severe hypertriglyceridemia'",
"    </a>",
"    above). In the absence of randomized trials that have demonstrated a reduction in first episodes of pancreatitis with therapy in such patients, agents are typically chosen based on their ability to reduce triglyceride levels, and based on their side effects. Typically patients are treated with fibrates, nicotinic acid, or fish oil, either alone or in combination, with a goal of lowering triglyceride levels below 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301366\">",
"    <span class=\"h3\">",
"     Fibrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrate therapy with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    can reduce triglyceride levels by 20 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/28\">",
"     28",
"    </a>",
"    ]. Gemfibrozil increases the risk of muscle toxicity induced by statin therapy. This risk can be minimized by using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    which are not extensively metabolized by CYP3A4 (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    ). Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    is also not metabolized by CYP3A4, it is recommended that the dosage be limited to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in patients being treated with gemfibrozil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/94\">",
"     94",
"    </a>",
"    ]. Fenofibrate does not increase statin levels, and it is considered a safer agent for combined therapy with a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reductions in triglyceride levels may be even greater in severe hypertriglyceridemia.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     Gemfibrozil",
"    </a>",
"    therapy, for example, can lower the serum triglyceride concentration by 70 percent in patients with very high serum triglycerides, and reduce plasma viscosity, which may contribute to clinical benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibrate therapy may increase the risk of pancreatitis in patients with normal or mildly elevated triglyceride levels (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link&amp;anchor=H8#H8\">",
"     \"Lipid lowering with fibric acid derivatives\", section on 'Toxicity and drug interactions'",
"    </a>",
"    ). Fibrates should not be administered for the purpose of reducing the risk of pancreatitis in patients with only mild to moderate elevations in triglyceride level: the risk of pancreatitis in such patients is very small (see",
"    <a class=\"local\" href=\"#H300298\">",
"     'Severe hypertriglyceridemia'",
"    </a>",
"    above), and fibrate therapy could be counterproductive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301487\">",
"    <span class=\"h3\">",
"     Nicotinic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotinic acid at doses of 1500 to 2000 mg daily can reduce triglyceride levels by 15 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/28\">",
"     28",
"    </a>",
"    ]. Nicotinic acid may worsen glucose tolerance in diabetic patients, although not all studies have found this effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. Glycemic control should be monitored carefully in diabetic patients treated with nicotinic acid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although reductions in triglyceride levels are typically smaller with nicotinic acid than with fibrates, nicotinic acid has some of the most suggestive data for any nonstatin medication that it may reduce cardiovascular risk, alone or in combination with a statin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H11#H11\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Use of medications other than statins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301630\">",
"    <span class=\"h3\">",
"     Fish oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fish oil supplements at doses &ge;3",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    eicosapentaenoic",
"    <span class=\"nowrap\">",
"     acid/docosahexaenoic",
"    </span>",
"    <span class=\"nowrap\">",
"     acid&nbsp;(EPA/DHA)",
"    </span>",
"    concentrate reduce VLDL production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/101-103\">",
"     101-103",
"    </a>",
"    ] and can lower the serum triglyceride concentration by as much as 50 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/102\">",
"     102",
"    </a>",
"    ]. However, their use is often limited by metabolic and gastrointestinal side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link&amp;anchor=H2#H2\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Fish oil and omega-3 fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active omega-3 fatty acids constitute only 30 to 50 percent of many fish oil supplements. In comparison, a commercial preparation (Lovaza in the United States and Omacor elsewhere) is 85 percent omega-3 fatty acids. In patients with severe hypertriglyceridemia, Lovaza (4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    reduced triglyceride levels by 45 percent, but raised LDL-C levels by 31 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/104\">",
"     104",
"    </a>",
"    ]. Another commercial preparation, Vascepa, is more than 95 percent icosapent-ethyl, the ethyl ester of EPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/105\">",
"     105",
"    </a>",
"    ]. Icosapent-ethyl (4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    also reduced triglyceride levels by up to 45 percent, but did not significantly affect LDL-C levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/106\">",
"     106",
"    </a>",
"    ]. This differential effect on LDL-C levels appears large enough to be potentially clinically meaningful, but larger trials comparing preparations in appropriate target populations are needed before we can recommend this newer and more expensive preparation over dual omega-3 fatty acid products. Additionally, trials with clinical endpoints will help determine whether these LDL-C effects translate into differences in clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H301679\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, in patients with refractory hypertriglyceridemia, combinations of statins, fibrates, nicotinic acid, and fish oil are typically used. There have been case reports of treating patients with marked symptoms with plasma",
"    <span class=\"nowrap\">",
"     exchange/plasmapheresis,",
"    </span>",
"    particularly in patients with acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/64,107\">",
"     64,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31064?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypertriglyceridemia-induced acute pancreatitis\", section on 'Apheresis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with type V hyperlipoproteinemia and very high triglyceride levels refractory to the above therapies, a report of five patients suggests that there may be benefit to the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    , a minimally absorbed drug that inhibits pancreatic and gastric lipases, blocks absorption of approximately 30 percent of ingested fat, and reduces intestinal chylomicron synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=see_link&amp;anchor=H8#H8\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\", section on 'Lipase inhibitors (Orlistat)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1153537602\">",
"    <span class=\"h3\">",
"     Monitoring response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapies vary in how quickly they reduce triglyceride levels. The majority of the response with nicotinic acid is seen in six weeks, with fish oil in two weeks, and a response to fibrates is seen as early as two weeks into therapy with a maximal effect in six to eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. Since combination therapy is commonly used, in practice we typically check triglyceride levels six to eight weeks after altering therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231026640\">",
"    <span class=\"h1\">",
"     SCREENING FAMILY MEMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While hypertriglyceridemia is frequently an acquired disorder, many of the causes are familial (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Disorders of triglyceride metabolism'",
"    </a>",
"    above). Given the risk of pancreatitis with very severe hypertriglyceridemia and the association with cardiovascular disease with somewhat less severe hypertriglyceridemia, in patients with triglyceride levels above 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who are otherwise healthy and have nothing to suggest an acquired disorder (eg, not obese, not diabetic, not hypothyroid) (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Acquired disorders'",
"    </a>",
"    above), we suggest screening first-degree relatives by measuring a fasting triglyceride level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300925\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) state that while a triglyceride level below 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      is desirable, the first step in management is to achieve the appropriate LDL-C target based on total cardiovascular risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/112\">",
"       112",
"      </a>",
"      ]. Pharmacologic therapy should only be considered in patients at high cardiovascular risk who also have triglycerides above 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and who cannot reduce these levels with lifestyle measures.",
"     </li>",
"     <li>",
"      The United States National Cholesterol Education Program (NCEP; Adult Treatment Panel [ATP] III) recommended that in all patients with borderline high or high triglycerides, the primary goal of therapy is to achieve the targets for LDL-C (",
"      <a class=\"graphic graphic_table graphicRef82504 \" href=\"mobipreview.htm?11/4/11340\">",
"       table 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67460 \" href=\"mobipreview.htm?10/46/10989\">",
"       table 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/47/35578/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, the following recommendations were made for various levels of elevated triglycerides:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When triglycerides are borderline high (150 to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.7 to 2.2",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      emphasis should be upon weight reduction and increased physical activity. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When triglycerides are high (200 to 499",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.3 to 5.7",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      non-HDL cholesterol becomes a secondary target of therapy after LDL-C. In addition to nonpharmacologic therapy, drug therapy can be considered in high-risk patients, including those who have had an acute myocardial infarction, to reach the non-HDL cholesterol goals (",
"      <a class=\"graphic graphic_table graphicRef53318 \" href=\"mobipreview.htm?2/46/2795\">",
"       table 10",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link&amp;anchor=H14#H14\">",
"       \"ATP III guidelines for treatment of high blood cholesterol\", section on 'Non-HDL-cholesterol'",
"      </a>",
"      ). These goals may be achieved by intensifying therapy with an LDL-C lowering drug, or by adding nicotinic acid or a fibrate (",
"      <a class=\"graphic graphic_table graphicRef75715 \" href=\"mobipreview.htm?21/47/22268\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pharmacologic therapy (including fish oil)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When triglycerides are very high (&ge;500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&ge;5.7",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      the initial goal is to prevent pancreatitis by lowering triglycerides with the combination of nonpharmacologic therapy and a triglyceride lowering drug such as a fibrate or nicotinic acid. Once triglycerides are below 500",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      LDL-C goals should be addressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/28/20930?source=see_link\">",
"       \"Patient information: High triglycerides (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H302377\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum triglyceride concentration can be stratified in terms of population percentiles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coronary risk (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions, epidemiology, and detection'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Normal &mdash; &lt;150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Borderline high &mdash; 150 to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7 to 2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      High &mdash; 200 to 499",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.3 to 5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Very high &mdash; &ge;500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;5.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In this topic, when discussing management, we refer to the range of fasting triglyceride levels from 150 to 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7 to 5.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      as &ldquo;mild to moderate&rdquo; hypertriglyceridemia and levels above 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      as &ldquo;severe&rdquo; hypertriglyceridemia.",
"     </li>",
"     <li>",
"      Although the contribution of triglycerides to cardiovascular risk has been debated in the past, it now seems clear that elevated triglyceride levels are independently associated with cardiovascular risk, particularly coronary risk. It remains uncertain, however, whether this association is causal, such that hypertriglyceridemia, independent of associated lipoprotein, inflammatory and hemostatic abnormalities, causes atherosclerosis. It is also uncertain whether lowering triglyceride levels reduces risk. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Triglycerides and atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are only limited data regarding which patients with hypertriglyceridemia require treatment and on the choice of therapies. (See",
"      <a class=\"local\" href=\"#H723637349\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic interventions such as weight loss in obese patients, aerobic exercise, avoidance of concentrated sugars and medications that raise serum triglyceride levels, and strict glycemic control in diabetics should be first-line therapy in patients with mild to moderate hypertriglyceridemia. Alcohol consumption can have both favorable and unfavorable effects on cardiovascular risk. We suggest that in patients with mild to moderate hypertriglyceridemia, men limit their alcohol consumption to no more than two drinks per day and women limit their consumption to no more than one drink per day (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other risk factors for cardiovascular disease, such as hypertension and smoking, should also be addressed. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In patients with severe hypertriglyceridemia (fasting triglyceride levels above 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11.3",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      we suggest a very low-fat diet and complete avoidance of alcohol (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for pharmacologic therapy directed at reducing triglycerides include fibrates, nicotinic acid, and fish oil. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Pharmacologic therapy (including fish oil)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild to moderate hypertriglyceridemia (150 to 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.7 to 5.7",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      and even in patients with triglyceride levels as high as 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.3",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      the main indication for therapy is reduction of cardiovascular (CV) risk. In patients where the goal of therapy is CV risk reduction:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decisions about initiating pharmacologic therapy should be based on global cardiovascular risk. Nearly all patients with known coronary heart disease (CHD) or a CHD risk equivalent (",
"      <a class=\"graphic graphic_table graphicRef71255 \" href=\"mobipreview.htm?43/30/44523\">",
"       table 4",
"      </a>",
"      ) will require therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Deciding whom to treat'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Identification of patients at risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a triglyceride level below 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in whom pharmacologic therapy is indicated, we suggest treatment with a statin rather than an agent targeted at reduction of triglycerides (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Given the lack of high-quality evidence directly comparing statin therapy with other treatment options, a reasonable alternative in such patients would be to treat them with fibrates, nicotinic acid, or fish oil. (See",
"      <a class=\"local\" href=\"#H723637365\">",
"       'Mild to moderate hypertriglyceridemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CHD or a CHD risk equivalent (",
"      <a class=\"graphic graphic_table graphicRef71255 \" href=\"mobipreview.htm?43/30/44523\">",
"       table 4",
"      </a>",
"      ) who have moderate hypertriglyceridemia (200 to 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.3 to 5.7",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and are intolerant of statin therapy, we suggest treatment with nicotinic acid or a fibrate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment with fish oil is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H723637365\">",
"       'Mild to moderate hypertriglyceridemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a triglyceride level above 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in whom pharmacologic therapy is indicated, we suggest treatment with a fibrate (such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      ), followed by the addition of a statin once the triglyceride levels are brought down (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Fish oil therapy is also an option. A reasonable alternative would be to treat lower-risk patients with a statin alone and to only add triglyceride-directed therapy in patients with CHD or a CHD risk equivalent (",
"      <a class=\"graphic graphic_table graphicRef71255 \" href=\"mobipreview.htm?43/30/44523\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H300298\">",
"       'Severe hypertriglyceridemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without a prior episode of pancreatitis, we suggest initiating pharmacologic therapy to reduce triglycerides with a goal of preventing pancreatitis when the level exceeds 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Even at this level of triglyceride elevation, the risk of pancreatitis appears to be quite small. Patients being treated for prevention of pancreatitis will often require combinations of triglyceride-lowering medications (ie, a fibrate, fish oil, nicotinic acid) to reduce the triglyceride level below 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.3",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H300298\">",
"       'Severe hypertriglyceridemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with hypertriglyceridemia and acute pancreatitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a prior episode of pancreatitis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31064?source=see_link\">",
"       \"Hypertriglyceridemia-induced acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/1\">",
"      Durrington P. Dyslipidaemia. Lancet 2003; 362:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/2\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/3\">",
"      Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009; 169:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/4\">",
"      Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/5\">",
"      Roncaglioni MC, Santoro L, D'Avanzo B, et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation 1992; 85:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/6\">",
"      Thompson WG, Gau GT. Hypertriglyceridemia and its pharmacologic treatment among US adults--invited commentary. Arch Intern Med 2009; 169:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/7\">",
"      Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 2001; 87:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/8\">",
"      Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/9\">",
"      Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/10\">",
"      Pare G, Anand SS. Mendelian randomisation, triglycerides, and CHD. Lancet 2010; 375:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/11\">",
"      Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000; 85:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/12\">",
"      Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995; 6:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/13\">",
"      Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/14\">",
"      Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/15\">",
"      Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation 1996; 94:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/16\">",
"      Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996; 94:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/17\">",
"      Stewart BF, Brown BG, Zhao XQ, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994; 23:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/18\">",
"      Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/19\">",
"      Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007; 147:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/20\">",
"      Haim M, Benderly M, Brunner D, et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/21\">",
"      Sprecher DL, Pearce GL, Cosgrove DM, et al. Relation of serum triglyceride levels to survival after coronary artery bypass grafting. Am J Cardiol 2000; 86:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/22\">",
"      Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/23\">",
"      Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/24\">",
"      Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/25\">",
"      Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999; 99:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/26\">",
"      Sprecher DL, Harris BV, Stein EA, et al. Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. A preliminary report. Circulation 1996; 94:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/27\">",
"      Hypertriglyceridaemia and vascular risk. Report of a meeting of physicians and scientists, University College London Medical School. Lancet 1993; 342:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/28\">",
"      Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007; 357:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/29\">",
"      Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/30\">",
"      Fukushima H, Kugiyama K, Sugiyama S, et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol 2001; 88:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/31\">",
"      DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/32\">",
"      McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/33\">",
"      Simpson HC, Mann JI, Meade TW, et al. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/34\">",
"      Humphries SE, Lane A, Green FR, et al. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/35\">",
"      Rosenson RS, Shott S, Lu L, Tangney CC. Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med 2001; 110:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/36\">",
"      Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998; 31:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/37\">",
"      Gaziano JM, Hennekens CH, O'Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/38\">",
"      Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/39\">",
"      Horowitz BS, Goldberg IJ, Merab J, et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993; 91:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/40\">",
"      Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/41\">",
"      F&ouml;ger B, Ritsch A, Doblinger A, et al. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996; 16:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/42\">",
"      Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/43\">",
"      Lamarche B, Tchernof A, Mauri&egrave;ge P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/44\">",
"      Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37:693.",
"     </a>",
"    </li>",
"    <li>",
"     Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: The Metabolic and Molecular Basis of Inherited Disease, 7th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw Hill, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/46\">",
"      Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/47\">",
"      O'Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998; 73:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/48\">",
"      Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/49\">",
"      Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998; 83:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/50\">",
"      Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/51\">",
"      Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/52\">",
"      Smellie WS. Hypertriglyceridaemia in diabetes. BMJ 2006; 333:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/53\">",
"      Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/54\">",
"      Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/55\">",
"      O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/56\">",
"      Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/57\">",
"      Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/58\">",
"      Fonarow GC, Deedwania P, Fonseca V, et al. Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. J Am Soc Hypertens 2009; 3:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/59\">",
"      Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/60\">",
"      Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/61\">",
"      Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/62\">",
"      Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipoproteinemia. A descriptive study in 32 families. Ann Intern Med 1977; 87:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/63\">",
"      Ghiselli G, Schaefer EJ, Zech LA, et al. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J Clin Invest 1982; 70:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/64\">",
"      Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998; 27:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/65\">",
"      Benlian P, De Gennes JL, Foubert L, et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996; 335:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/66\">",
"      Nordestgaard BG, Abildgaard S, Wittrup HH, et al. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997; 96:1737.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.bbc.co.uk/news/health-20179561 (Accessed on November 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/68\">",
"      Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/69\">",
"      Pajukanta P, Nuotio I, Terwilliger JD, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet 1998; 18:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/70\">",
"      Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992; 12:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/71\">",
"      Yang WS, Nevin DN, Peng R, et al. A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc Natl Acad Sci U S A 1995; 92:4462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/72\">",
"      Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999; 40:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/73\">",
"      Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med 1994; 120:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/74\">",
"      Huang Y, Rall SC Jr, Mahley RW. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler Thromb Vasc Biol 1997; 17:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/75\">",
"      Dong LM, Parkin S, Trakhanov SD, et al. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 1996; 3:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/76\">",
"      Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987; 2:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/77\">",
"      Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/78\">",
"      Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990; 81:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/79\">",
"      Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/80\">",
"      Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/81\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/82\">",
"      Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/83\">",
"      ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/84\">",
"      Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/85\">",
"      Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/86\">",
"      Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/87\">",
"      Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis 2011; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/88\">",
"      Lederle FA, Bloomfield HE. Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence? Ann Intern Med 2012; 157:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/89\">",
"      McBride PE. Triglycerides and risk for coronary heart disease. JAMA 2007; 298:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/90\">",
"      Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992; 37:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/91\">",
"      Gotto AM Jr. Hypertriglyceridemia: risks and perspectives. Am J Cardiol 1992; 70:19H.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/92\">",
"      Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991; 325:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/93\">",
"      Pownall HJ, Ballantyne CM, Kimball KT, et al. Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Arch Intern Med 1999; 159:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/94\">",
"      Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/95\">",
"      Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/96\">",
"      Stein JH, Rosenson RS. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 1998; 137:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/97\">",
"      Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/98\">",
"      Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994; 121:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/99\">",
"      Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/100\">",
"      Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/101\">",
"      Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984; 74:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/102\">",
"      Harris WS, Connor WE, Illingworth DR, et al. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res 1990; 31:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/103\">",
"      Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/104\">",
"      Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/105\">",
"      Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/106\">",
"      Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/107\">",
"      Lennertz A, Parhofer KG, Samtleben W, Bosch T. Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 1999; 3:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/108\">",
"      Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002; 89:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/109\">",
"      Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008; 6:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/110\">",
"      Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997; 54:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/111\">",
"      Capell WH, DeSouza CA, Poirier P, et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003; 23:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/47/35578/abstract/112\">",
"      European Association for Cardiovascular Prevention &amp; Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4570 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35578=[""].join("\n");
var outline_f34_47_35578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H302377\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS, EPIDEMIOLOGY, AND DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRIGLYCERIDES AND ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H470902041\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H470902414\">",
"      Cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Importance of associated abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DISORDERS OF TRIGLYCERIDE METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acquired disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chylomicronemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Familial hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Familial combined hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Familial dysbetalipoproteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypertriglyceridemia and serum cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H723637349\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H723637365\">",
"      Mild to moderate hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H300298\">",
"      Severe hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pharmacologic therapy (including fish oil)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H301366\">",
"      - Fibrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H301487\">",
"      - Nicotinic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H301630\">",
"      - Fish oil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H301679\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1153537602\">",
"      - Monitoring response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231026640\">",
"      SCREENING FAMILY MEMBERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H300925\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H302377\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4570\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4570|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/29/8657\" title=\"figure 1\">",
"      VLDL metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/4/5199\" title=\"figure 2\">",
"      HDL metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/40/16014\" title=\"figure 3\">",
"      Lipids and premature CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/9/6302\" title=\"figure 4\">",
"      TG LDL HDL and coronary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4570|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/50/12066\" title=\"picture 1\">",
"      Hypertriglyceride milky plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/38/32353\" title=\"picture 2\">",
"      Eruptive xanthomata forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/55/37746\" title=\"picture 3\">",
"      Tuberoeruptive xanthomata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/32/11776\" title=\"picture 4\">",
"      Striate palmar xanthomata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4570|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/51/21307\" title=\"table 1\">",
"      Fredrickson classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/63/19453\" title=\"table 2\">",
"      Normal values for lipid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/34/39467\" title=\"table 3\">",
"      Causes of hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/30/44523\" title=\"table 4\">",
"      CHD risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/40/8845\" title=\"table 5\">",
"      Glycemic index and load values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/29/41435\" title=\"table 6\">",
"      Ingested oz for EPA DHA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/47/22268\" title=\"table 7\">",
"      Effects of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/4/11340\" title=\"table 8\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/46/10989\" title=\"table 9\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/46/2795\" title=\"table 10\">",
"      Non HDL cholesterol goals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44659?source=related_link\">",
"      Antihypertensive drugs and lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/21/31064?source=related_link\">",
"      Hypertriglyceridemia-induced acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28550?source=related_link\">",
"      Lipid abnormalities in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/61/13274?source=related_link\">",
"      Maternal endocrine and metabolic adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/28/20930?source=related_link\">",
"      Patient information: High triglycerides (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_47_35579="Specifications for confocal miniprobes";
var content_f34_47_35579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Specifications for confocal miniprobes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Product name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gastroflex UHD&trade;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Coloflex UHD&trade;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cholangioflex&trade;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alveoflex&trade;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compatible operating channel",
"       </td>",
"       <td>",
"        &ge;2.8 mm",
"       </td>",
"       <td>",
"        &ge;2.8 mm",
"       </td>",
"       <td>",
"        &ge;1.2 mm",
"       </td>",
"       <td>",
"        &ge;2.2 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Field of view",
"       </td>",
"       <td>",
"        240 microns",
"       </td>",
"       <td>",
"        240 microns",
"       </td>",
"       <td>",
"        320 microns",
"       </td>",
"       <td>",
"        600 microns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confocal depth",
"       </td>",
"       <td>",
"        55 to 65 microns",
"       </td>",
"       <td>",
"        55 to 65 microns",
"       </td>",
"       <td>",
"        40 to 70 microns",
"       </td>",
"       <td>",
"        0 to 50 microns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resolution",
"       </td>",
"       <td>",
"        1 micron",
"       </td>",
"       <td>",
"        1 micron",
"       </td>",
"       <td>",
"        3.5 microns",
"       </td>",
"       <td>",
"        3.5 microns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Length",
"       </td>",
"       <td>",
"        3 m",
"       </td>",
"       <td>",
"        4 m",
"       </td>",
"       <td>",
"        4 m",
"       </td>",
"       <td>",
"        3 m",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Available miniprobes for confocal laser endomicroscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mauna Kea Technologies.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35579=[""].join("\n");
var outline_f34_47_35579=null;
var title_f34_47_35580="Diseases hosts Microsporidia";
var content_f34_47_35580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hosts and diseases associated with microsporidia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nonhuman species",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        HIV",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterocytozooan bieneusi",
"       </td>",
"       <td>",
"        Pigs, primates",
"       </td>",
"       <td>",
"        Intestinal, hepatobiliary",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitozooan intestinalis (Septata intestinalis)",
"       </td>",
"       <td>",
"        Some mammals",
"       </td>",
"       <td>",
"        Disseminated",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitozooan hellem",
"       </td>",
"       <td>",
"        Parakeets",
"       </td>",
"       <td>",
"        Disseminated",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitozooan cuniculi",
"       </td>",
"       <td>",
"        Rabbits, mice, cats, foxes, dogs",
"       </td>",
"       <td>",
"        Corneal stroma",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nosema connori",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Disseminated",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nosema ocularum",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Corneal stroma",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nosema-like species",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Corneal stroma",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trachipleistophora hominis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Skeletal muscle, nasal sinuses",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trachipleistophora antropophtera",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Disseminated",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleistophora spp",
"       </td>",
"       <td>",
"        Fish",
"       </td>",
"       <td>",
"        Skeletal muscle",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vittaforma corneae (Nosema corneae)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Corneal stroma",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microsporidum spp. (species not fully classified)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Disseminated",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35580=[""].join("\n");
var outline_f34_47_35580=null;
var title_f34_47_35581="IHC data about ER neg rate";
var content_f34_47_35581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Immunohistochemistry data about ER-negative rate from the Intermountain Healthcare Study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 373px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ER: estrogen receptor.",
"    </div>",
"    <div class=\"reference\">",
"     Based on data from: Nkoy FL, Hammond ME, Rees W, et al. Arch Pathol Lab Med 2010; 134:606.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35581=[""].join("\n");
var outline_f34_47_35581=null;
var title_f34_47_35582="Fibrosis progression ex thal";
var content_f34_47_35582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Freedom from progression of hepatic fibrosis by iron and HCV status after hematopoetic cell transplantation for beta thalassemia major",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 309px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the probability of surviving without progression of hepatic fibrosis (percent, y axis) versus time after hematopoietic cell transplantation (months, x axis) in 211 patients with thalassemia major who were not treated with iron chelation or antiviral therapy. Patients were stratified into six groups according to hepatic iron concentration (low: 0.5 to 5.6, medium: 5.7 to 12.7, high &gt;12.7 mg/g dry weight) and hepatitis C virus (HCV) status (positive, negative). HCV-negative patients with low or medium hepatic iron levels did not show progression of fibrosis and were grouped together (uppermost curve, red).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Angelucci, E, et al. Blood 2002; 100:17.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35582=[""].join("\n");
var outline_f34_47_35582=null;
var title_f34_47_35583="Face Arm Speech Test";
var content_f34_47_35583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Face Arm Speech Test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 527px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harbison J, Hossain O, Jenkinson D, et al. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003; 34:71. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_47_35583=[""].join("\n");
var outline_f34_47_35583=null;
